

# Baricitinib plus Remdesivir for Hospitalized Adults with

New England Journal of Medicine

384, 795-807

DOI: [10.1056/nejmoa2031994](https://doi.org/10.1056/nejmoa2031994)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2. Scientific Reports, 2020, 10, 17806.	1.6	58
2	What GI Physicians Need to Know During COVID-19 Pandemic. Digestive Diseases and Sciences, 2020, 66, 2865-2875.	1.1	7
3	Recommendations for treatment of critically ill patients with COVID-19. Der Anaesthetist, 2020, , 1.	0.5	22
4	After 62 years of regulating immunity, dexamethasone meets COVID-19. Nature Reviews Immunology, 2020, 20, 587-588.	10.6	108
5	Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ, The, 2020, 370, m2980.	3.0	592
6	The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients. Inflammopharmacology, 2021, 29, 91-100.	1.9	215
7	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients. Wiener Klinische Wochenschrift, 2021, 133, 284-291.	1.0	24
8	Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology, 2021, 19, 141-154.	13.6	3,334
10	Learning from the past: development of safe and effective COVID-19 vaccines. Nature Reviews Microbiology, 2021, 19, 211-219.	13.6	126
11	The COVID-19 pandemic: consequences for nephrology. Nature Reviews Nephrology, 2021, 17, 81-82.	4.1	81
12	Thrombocytopeny and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nature Reviews Cardiology, 2021, 18, 194-209.	6.1	304
13	COVID-19 pandemic in Japan. Rheumatology International, 2021, 41, 1-5.	1.5	51
14	COVID-19 and the second wave during autumn: preventive strategies in cardiac and thoracic surgery divisions. European Surgery - Acta Chirurgica Austriaca, 2021, 53, 37-39.	0.3	1
15	DGI recommendations for COVID-19 pharmacotherapy. Infection, 2021, 49, 369-370.	2.3	3
16	Remdesivir in COVID-19 management: availability and relevance to low- and middle-income countries. Drugs and Therapy Perspectives, 2021, 37, 26-28.	0.3	2
17	Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate. Journal of Thrombosis and Thrombolysis, 2021, 51, 649-656.	1.0	17
18	Emergency Use Authorization for Remdesivir and Its Potential Implications. Therapeutic Innovation and Regulatory Science, 2021, 55, 270-271.	0.8	4
19	What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19. International Journal of Critical Illness and Injury Science, 2021, 11, 109.	0.2	1

#	ARTICLE	IF	CITATIONS
20	COVID-19: A game of drugs, vaccines, hope and death!. Indian Journal of Anaesthesia, 2021, 65, 434.	0.3	9
21	Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. Topics in Current Chemistry, 2021, 379, 4.	3.0	15
22	In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors. Protein Journal, 2021, 40, 296-309.	0.7	47
23	Update: Drug treatment options for coronavirus disease 2019 (COVID-19). BioScience Trends, 2021, 15, 345-349.	1.1	5
24	Pharmacologic Treatment of COVID-19: Evidence-Based Update. Indian Journal of Respiratory Care, 2021, 10, S34-S38.	0.1	3
25	Efficacy of Proxalutamide (GT0918) in Hospitalized COVID-19 Patients. SSRN Electronic Journal, 0, , .	0.4	0
26	Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology, 2021, 60, vi12-vi20.	0.9	26
28	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. , 2021, , 27-89.		0
29	Pulmonary cavitation: an under-recognized late complication of severe COVID-19 lung disease. BMC Pulmonary Medicine, 2021, 21, 24.	0.8	43
30	Modulating the host immune response to fight against COVID-19: Where are we in 2021?. Virulence, 2021, 12, 1732-1736.	1.8	8
31	Recent biotechnological advances as potential intervention strategies against COVID-19. 3 Biotech, 2021, 11, 41.	1.1	10
33	Response to: "Correspondence on "Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis" by Lee. Annals of the Rheumatic Diseases, 2023, 82, e84-e84.	0.5	20
34	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358.	0.4	3
35	SARS-CoV-2: Outline, Prevention, and Decontamination. Pathogens, 2021, 10, 114.	1.2	12
36	Haemophagocytic syndrome and COVID-19. Clinical Rheumatology, 2021, 40, 1233-1244.	1.0	53
37	Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective. Lung India, 2021, 38, 382-386.	0.3	5
38	Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. Annals of the Rheumatic Diseases, 2021, 80, 803-815.	0.5	31
40	Just the facts: updates in COVID-19 therapeutics. Canadian Journal of Emergency Medicine, 2021, 23, 283-285.	0.5	0

#	ARTICLE	IF	CITATIONS
41	Case Report: Takotsubo Syndrome Associated With Novel Coronavirus Disease 2019. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 614562.	1.1	12
42	Reports of three long-term lung disease following SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2021, 93, 2585-2587.	2.5	0
43	Pediatric Coronavirus Disease 2019: Clinical Features and Management. <i>Indian Pediatrics</i> , 2021, 58, 453-460.	0.2	5
44	SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics. <i>Expert Review of Proteomics</i> , 2021, 18, 105-118.	1.3	10
45	COVID-19 illness and autoimmune diseases: recent insights. <i>Inflammation Research</i> , 2021, 70, 407-428.	1.6	13
47	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706.	0.5	37
48	Treatment of Critically Ill Patients with Coronavirus Disease 2019. <i>Korean Journal of Medicine</i> , 2021, 96, 22-29.	0.1	1
49	COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?. <i>Journal of Ovarian Research</i> , 2021, 14, 28.	1.3	17
50	Baricitinib and dexamethasone for hospitalized patients with COVID-19. <i>Cleveland Clinic Journal of Medicine</i> , 2021, , .	0.6	18
51	Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series. <i>European Journal of Haematology</i> , 2021, 106, 654-661.	1.1	30
52	Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis. <i>Frontiers in Immunology</i> , 2021, 12, 614704.	2.2	77
53	Adjunctive Nutraceutical Therapies for COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1963.	1.8	33
54	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , 2021, 10, 783.	1.0	18
55	COVID-19: Reasons for Guarded Optimism. <i>Pharmaceutical Medicine</i> , 2021, 35, 67-69.	1.0	0
56	Balancing Healthcare and Economy Amidst the COVID-19 Pandemic: An Indian Experience. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 827-833.	1.2	6
57	The impact of COVID-19 on kidney transplantation and the kidney transplant recipient " One year into the pandemic. <i>Transplant International</i> , 2021, 34, 612-621.	0.8	40
58	Dysregulated transcriptional responses to SARS-CoV-2 in the periphery. <i>Nature Communications</i> , 2021, 12, 1079.	5.8	81
59	Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 213-218.	2.1	14

#	ARTICLE	IF	CITATIONS
60	Metal-Bound Methisazone; Novel Drugs Targeting Prophylaxis and Treatment of SARS-CoV-2, a Molecular Docking Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2977.	1.8	4
61	Serum Î2-microglobulin levels in Coronavirus disease 2019 (Covid-19): Another prognosticator of disease severity?. <i>PLoS ONE</i> , 2021, 16, e0247758.	1.1	12
62	Targeting tumour necrosis factor to ameliorate viral pneumonia. <i>FEBS Journal</i> , 2022, 289, 883-900.	2.2	19
63	Review of studies of severe acute respiratory syndrome related coronavirusâ€“2 pathogenesis in human organoid models. <i>Reviews in Medical Virology</i> , 2021, 31, e2227.	3.9	10
64	Treatment of COVID-19: a review of current and prospective pharmacotherapies. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2021, 82, 1-9.	0.2	14
65	Interleukin-6 blocking agents for treating COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2021, 2021, CD013881.	1.5	106
66	Potential COVIDâ€“19 Therapeutic Agents and Vaccines: An Evidenceâ€“Based Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 429-460.	1.0	22
67	Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control. <i>Drug Delivery and Translational Research</i> , 2021, 11, 1420-1437.	3.0	18
68	Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. <i>Nature Medicine</i> , 2021, 27, 401-410.	15.2	127
69	Anti-Inflammation, Immunomodulation and Therapeutic Repair in Current Clinical Trials for the Management of COVID-19. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1345-1356.	2.0	1
71	COVID-19 and rheumatology: A year later. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 31-36.	0.2	7
72	Coronavirus disease 2019 (COVID-19) and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 5-30.	0.2	28
73	Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 649922.	1.1	15
75	Current evidence for COVID-19 therapies: a systematic literature review. <i>European Respiratory Review</i> , 2021, 30, 200384.	3.0	37
76	Real-life use of remdesivir in hospitalized patients with COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 136-140.	0.5	20
77	SARSâ€“CoVâ€“2 and pediatric solid organ transplantation: Current knowns and unknowns. <i>Pediatric Transplantation</i> , 2021, 25, e13986.	0.5	6
78	Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 74, 95-104.	2.9	31
79	Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1801-1814.	1.8	67

#	ARTICLE	IF	CITATIONS
80	Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients. Current Transplantation Reports, 2021, 8, 127-139.	0.9	31
81	The in-vitro effect of famotidine on SARS-CoV-2 proteases and virus replication. Scientific Reports, 2021, 11, 5433.	1.6	22
82	Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. Inflammopharmacology, 2021, 29, 343-366.	1.9	9
83	Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection. European Journal of Immunology, 2021, 51, 1071-1075.	1.6	31
84	Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 224, 39-48.	1.9	43
85	Seroconversion stages COVID19 into distinct pathophysiological states. ELife, 2021, 10, .	2.8	40
86	Temporal variations in the severity of COVID-19 illness by race and ethnicity. BMJ Nutrition, Prevention and Health, 2021, 4, 166-173.	1.9	3
89	The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19. Frontiers in Medicine, 2021, 8, 637647.	1.2	25
90	Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials. Clinical Infectious Diseases, 2022, 74, 352-358.	2.9	36
91	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2021, 57, 2100048.	3.1	152
93	Experimental therapies under investigation for COVID-19. Journal of Community Hospital Internal Medicine Perspectives, 2021, 11, 187-193.	0.4	3
96	Neurological risks and benefits of cytokine-based treatments in coronavirus disease 2019: from preclinical to clinical evidence. British Journal of Pharmacology, 2021, , .	2.7	2
97	COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development. Experimental Biology and Medicine, 2021, 246, 1533-1540.	1.1	2
98	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). Clinical Microbiology and Infection, 2021, 27, 389-395.	2.8	37
99	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. Frontiers in Pharmacology, 2021, 12, 632677.	1.6	65
100	Baricitinib Therapy in Covid-19 Pneumonia â€” An Unmet Need Fulfilled. New England Journal of Medicine, 2021, 384, 867-869.	13.9	56
101	Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia. Hamostaseologie, 2021, 41, 190-196.	0.9	8
102	Can Yogic Breathing Techniques Like Simha Kriya and Isha Kriya Regulate COVID-19-Related Stress?. Frontiers in Psychology, 2021, 12, 635816.	1.1	8

#	ARTICLE	IF	CITATIONS
104	Cutaneous Manifestations of COVID-19: Characteristics, Pathogenesis, and the Role of Dermatology in the Pandemic. , 2021, 107, 209-215.		3
105	Repositioned Drugs for COVID-19â€™the Impact on Multiple Organs. SN Comprehensive Clinical Medicine, 2021, 3, 1484-1501.	0.3	3
106	IFN-Î³ and TNF-Î± drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation. Genome Medicine, 2021, 13, 64.	3.6	128
107	Neutralizing monoclonal antibodies for treatment of COVID-19. Nature Reviews Immunology, 2021, 21, 382-393.	10.6	568
109	Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. Nature Medicine, 2021, 27, 668-676.	15.2	120
110	Applications and challenges of AI-based algorithms in the COVID-19 pandemic. BMJ Innovations, 2021, 7, 387-398.	1.0	17
112	Targeting hyperinflammation in infection: can we harness the COVID-19 therapeutics momentum to end the dengue drugs drought?. Lancet Microbe, The, 2021, 2, e277-e278.	3.4	5
113	Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?. Rheumatology, 2021, 60, e371.	0.9	0
116	COVID-19 and Disease-Modifying Anti-rheumatic Drugs. Current Rheumatology Reports, 2021, 23, 28.	2.1	15
117	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. Science Progress, 2021, 104, 003685042110169.	1.0	15
118	Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics. Pharmaceutics, 2021, 13, 494.	2.0	3
119	Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. Cancer Discovery, 2021, 11, 1336-1344.	7.7	20
120	Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARSâ€CoVâ€2 infection in vitro. British Journal of Pharmacology, 2021, 178, 2339-2350.	2.7	74
121	Potential drug targets of SARS-CoV-2: From genomics to therapeutics. International Journal of Biological Macromolecules, 2021, 177, 1-9.	3.6	77
122	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. Journal of Infection, 2021, 82, 58-66.	1.7	44
123	Knowledge Graphs for COVID-19: An Exploratory Review of the Current Landscape. Journal of Personalized Medicine, 2021, 11, 300.	1.1	18
124	IL-6 modulation for COVID-19: the right patients at the right time?. , 2021, 9, e002285.		32
125	2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. European Journal of Cancer, 2021, 147, 154-160.	1.3	34

#	ARTICLE	IF	CITATIONS
127	Çocuklarda COVID-19 Tedavisinde Antiviral Açılımlar. Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 2021, 10, 330.	0.0	0
128	A signaling pathway-driven bioinformatics pipeline for predicting therapeutics against emerging infectious diseases. F1000Research, 2021, 10, 330.	0.8	4
129	COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. Current Medical Research and Opinion, 2021, 37, 929-938.	0.9	9
130	Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications. Journal of Inflammation Research, 2021, Volume 14, 1487-1510.	1.6	50
131	Attenuation of COVID-19-induced cytokine storm in a young male patient with severe respiratory and neurological symptoms. Wiener Klinische Wochenschrift, 2021, 133, 973-978.	1.0	6
132	Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 2848-2865.	2.9	102
133	Effects of early corticosteroid use in patients with severe coronavirus disease 2019. BMC Infectious Diseases, 2021, 21, 506.	1.3	9
134	Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices?. International Journal of Molecular Sciences, 2021, 22, 5457.	1.8	8
135	Greetings from the editor. Annals of the Rheumatic Diseases, 2021, 80, 677-678.	0.5	2
136	JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia, 2021, 35, 2616-2620.	3.3	63
137	Infection-induced inflammation from specific inborn errors of immunity to COVID-19. FEBS Journal, 2021, 288, 5021-5041.	2.2	12
138	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals of the Rheumatic Diseases, 2021, 80, 1137-1146.	0.5	151
139	Management of severe covid-19: progress and promise. BMJ, The, 2021, 373, n1147.	3.0	6
140	COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. Archives of Pharmacal Research, 2021, 44, 499-513.	2.7	18
141	The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Molecular Cancer, 2021, 20, 76.	7.9	42
142	Characteristics, management, and prognosis of elderly patients with COVID-19 admitted in the ICU during the first wave: insights from the COVID-ICU study. Annals of Intensive Care, 2021, 11, 77.	2.2	44
143	Adenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cells. Scientific Reports, 2021, 11, 9561.	1.6	1
144	Current advances in pharmacological treatments for patients with COVID-19. Journal of the Korean Medical Association, 2021, 64, 375-385.	0.1	0



#	ARTICLE	IF	CITATIONS
147	Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh. <i>BMC Infectious Diseases</i> , 2021, 21, 427.	1.3	35
148	Existing Drugs Considered as Promising in COVID-19 Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5434.	1.8	24
149	Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1323-1330.	1.8	26
150	Overview of SARS-CoV-2 infection in adults living with HIV. <i>Lancet HIV</i> , 2021, 8, e294-e305.	2.1	129
151	Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study. <i>Nutrients</i> , 2021, 13, 1760.	1.7	71
152	Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. <i>Infectious Diseases of Poverty</i> , 2021, 10, 71.	1.5	42
153	COVID-19 in Solid Organ Transplantation: Disease Severity and Clinical Update. <i>Transplantation Proceedings</i> , 2021, 53, 1227-1236.	0.3	13
154	Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2021, 40, 665-706.	0.4	12
156	Development of leading first-generation vaccines against SARS-CoV-2. <i>Microbes and Infection</i> , 2021, 23, 104841.	1.0	0
157	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. <i>Klinische Monatsblätter Für Augenheilkunde</i> , 2021, 238, 569-578.	0.3	6
158	Current Strategies of Antiviral Drug Discovery for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671263.	1.6	75
159	3D human liver spheroids for translational pharmacology and toxicology. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 5-15.	1.2	25
160	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. , 2021, 9, e002392.		9
161	COVID-19: The therapeutic landscape. <i>Med</i> , 2021, 2, 493-497.	2.2	20
162	COVID-2019 fundamentals. <i>Journal of the American Dental Association</i> , 2021, 152, 354-363.	0.7	10
163	Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2. <i>EMBO Molecular Medicine</i> , 2021, 13, e14045.	3.3	36
164	Risks and Benefits of Kidney Transplantation during the COVID-19 Pandemic: Transplant or Not Transplant?. <i>Kidney360</i> , 2021, 2, 1179-1187.	0.9	9
166	JAK inhibitors: Ten years after. <i>European Journal of Immunology</i> , 2021, 51, 1615-1627.	1.6	49

#	ARTICLE	IF	CITATIONS
167	2019 Coronavirus disease (COVID-19): contribution of rheumatology. <i>Terapevticheskii Arkhiv</i> , 2021, 93, .	0.2	6
168	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 733-745.	0.9	24
169	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2 "Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	0.6	88
170	COVID-19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE). <i>Bulletin Du Cancer</i> , 2021, 108, 490-500.	0.6	8
171	Drug combination therapy for emerging viral diseases. <i>Drug Discovery Today</i> , 2021, 26, 2367-2376.	3.2	65
172	Overview of COVID-19 Disease: Virology, Epidemiology, Prevention Diagnosis, Treatment, and Vaccines. <i>Biologics</i> , 2021, 1, 2-40.	2.3	16
173	Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3398-3407.	1.1	1
175	COVID-19's natural course among ambulatory monitored outpatients. <i>Scientific Reports</i> , 2021, 11, 10124.	1.6	5
177	COVID-19 pneumonia in Galicia (Spain): Impact of prognostic factors and therapies on mortality and need for mechanical ventilation. <i>PLoS ONE</i> , 2021, 16, e0253465.	1.1	1
178	Therapeutic Targeting of Transcription Factors to Control the Cytokine Release Syndrome in COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 673485.	1.6	10
179	The role of antirheumatics in patients with COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e447-e459.	2.2	36
180	Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , 2021, 8, 691712.	1.2	11
181	Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 621440.	2.2	26
182	SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?. <i>Journal of Clinical Immunology</i> , 2021, 41, 1502-1506.	2.0	18
183	Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2866-2881.	2.7	59
184	Clinical Management of COVID-19 Patients " An Update. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 4-10.	2.5	33
185	The Immunopathobiology of SARS-CoV-2 Infection. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	9
186	IL-13 is a driver of COVID-19 severity. <i>JCI Insight</i> , 2021, 6, .	2.3	80

#	ARTICLE	IF	CITATIONS
187	Druggability of cavity pockets within SARS-CoV-2 spike glycoprotein and pharmacophore-based drug discovery. <i>Future Virology</i> , 2021, 16, 389-397.	0.9	10
189	Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir. <i>Frontiers in Immunology</i> , 2021, 12, 680188.	2.2	8
190	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). <i>BioMed Research International</i> , 2021, 2021, 1-20.	0.9	13
191	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. <i>Current HIV/AIDS Reports</i> , 2021, 18, 261-270.	1.1	5
192	Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1245-1246.	0.5	10
193	Baricitinib: From Rheumatoid Arthritis to COVID-19. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1274-1285.	1.0	40
194	COVID-19: Sleep, Circadian Rhythms and Immunity – Repurposing Drugs and Chronotherapeutics for SARS-CoV-2. <i>Frontiers in Neuroscience</i> , 2021, 15, 674204.	1.4	8
195	Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis. <i>Journal of the Formosan Medical Association</i> , 2021, 120, S77-S85.	0.8	5
197	COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. , 2021, 9, e002630.		76
199	Genome-wide association studies in ARDS: SNPing the tangled web of heterogeneity. <i>Intensive Care Medicine</i> , 2021, 47, 782-785.	3.9	1
200	The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. <i>ESMO Open</i> , 2021, 6, 100123.	2.0	10
201	COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 705-715.	8.2	26
202	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 547-560.	1.3	37
203	The Pro-Inflammatory Chemokines CXCL9, CXCL10 and CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-Dependent Manner. <i>Viruses</i> , 2021, 13, 1062.	1.5	88
204	Review of epidemic, containment strategies, clinical management, and economic evaluation of COVID-19 pandemic. <i>Journal of the Formosan Medical Association</i> , 2021, 120, S6-S18.	0.8	16
205	Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. <i>ACS Central Science</i> , 2021, 7, 1245-1260.	5.3	115
206	Three-Dimensional Cell Cultures as a Research Platform in Lung Diseases and COVID-19. <i>Tissue Engineering and Regenerative Medicine</i> , 2021, 18, 735-745.	1.6	10
207	Suggested Considerations for the Treatment of Rheumatic Diseases in Adult Patients With COVID-19: Comment on the Article by Mikuls et al. <i>Arthritis and Rheumatology</i> , 2021, 73, 2355-2355.	2.9	0

#	ARTICLE	IF	CITATIONS
208	Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1407-1418.	1.8	5
209	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. <i>Cells</i> , 2021, 10, 1412.	1.8	6
210	Update in COVID-19 2020. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1462-1471.	2.5	13
211	Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e410-e418.	2.2	57
212	Clinical frailty score as an independent predictor of outcome in COVID-19 hospitalised patients. <i>European Geriatric Medicine</i> , 2021, 12, 1065-1073.	1.2	9
213	Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. <i>Scientific Reports</i> , 2021, 11, 13208.	1.6	24
214	Calcifediol Treatment and COVID-19-Related Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4017-e4027.	1.8	60
215	Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic. <i>Metabolism Open</i> , 2021, 10, 100096.	1.4	27
216	A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?. <i>Arthritis and Rheumatology</i> , 2021, 73, 2166-2178.	2.9	43
218	Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 767-775.	1.5	32
219	Therapeutic approaches to tackle COVID-19: An overview. <i>Indian Journal of Pharmacy and Pharmacology</i> , 2021, 8, 121-135.	0.1	0
220	American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2. <i>Arthritis and Rheumatology</i> , 2021, 73, e46-e59.	2.9	9
221	The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 211-229.	2.0	10
223	Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN- $\beta$ . <i>Journal of Clinical Immunology</i> , 2021, 41, 1425-1442.	2.0	39
224	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3419-3428.	1.6	25
225	Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19. <i>Journal of Personalized Medicine</i> , 2021, 11, 668.	1.1	16
226	Safeguarding COVID-19 and cancer management: drug design and therapeutic approach. <i>Open Research Europe</i> , 0, 1, 77.	2.0	0
227	Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 239-254.	0.2	40

#	ARTICLE	IF	CITATIONS
229	Initial clinical characteristics of gravid severe acute respiratory syndrome coronavirus 2â€“positive patients and the risk of progression to severe coronavirus disease 2019. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100365.	1.3	6
230	Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?. Pharmaceutics, 2021, 13, 1181.	2.0	4
231	Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. Biomedicine and Pharmacotherapy, 2021, 139, 111642.	2.5	50
232	Tocilizumab for the treatment of nonâ€“critical COVIDâ€“19 pneumonia: an overview of the rationale and clinical evidence to date. Expert Review of Clinical Pharmacology, 2021, 14, 1279-1287.	1.3	4
233	Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report. Journal of the Nepal Medical Association, 2021, 59, 593-596.	0.1	1
234	The role of immunomodulatory medications in the treatment of COVID-19. Current Opinion in Rheumatology, 2021, 33, 431-445.	2.0	4
235	A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. European Respiratory Journal, 2021, 58, 2100673.	3.1	32
237	Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany. RMD Open, 2021, 7, e001687.	1.8	28
238	Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceutics, 2021, 14, 738.	1.7	29
239	Baricitinib reduces 30â€“day mortality in older adults with moderateâ€“toâ€“severe <scp>COVID</scp>â€“19 pneumonia. Journal of the American Geriatrics Society, 2021, 69, 2752-2758.	1.3	25
240	N-Acetylcysteine as Adjuvant Therapy for COVID-19 â€“ A Perspective on the Current State of the Evidence. Journal of Inflammation Research, 2021, Volume 14, 2993-3013.	1.6	31
241	Use of placebo in clinical trials in COVID-19 pandemic times: considerations on pros, cons, challenges and limitations. Minerva Medica, 2021, , .	0.3	3
242	Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. Life, 2021, 11, 753.	1.1	14
243	Tocilizumab and SARS-CoV-2 (COVID-19): An Evolving Story, the Picture Is Clearer. Infectious Diseases in Clinical Practice, 2021, 29, e199-e201.	0.1	0
244	Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. Pharmaceutics, 2021, 14, 736.	1.7	15
245	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infectious Diseases and Therapy, 2021, 10, 1837-1885.	1.8	28
246	Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. New England Journal of Medicine, 2021, 385, 406-415.	13.9	342
247	COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes. Current Opinion in Pulmonary Medicine, 2021, 27, 463-471.	1.2	7

#	ARTICLE	IF	CITATIONS
248	Distinctive features of severe SARS-CoV-2 pneumonia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	49
249	Remdesivir shifts circadian rhythmicity to eveningness; similar to the most prevalent chronotype in ADHD. <i>Journal of Neural Transmission</i> , 2021, 128, 1159-1168.	1.4	5
250	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. <i>Health Data Science</i> , 2021, 2021, .	1.1	9
252	Fulminant Myocarditis With ST Elevation and Cardiogenic Shock in a SARS-CoV-2 Patient. <i>Cureus</i> , 2021, 13, e16149.	0.2	8
253	COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic. <i>World Journal of Clinical Cases</i> , 2021, 9, 5352-5357.	0.3	3
254	Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04459.	0.2	2
255	Contemporary narrative review of treatment options for COVID-19. <i>Respirology</i> , 2021, 26, 745-767.	1.3	12
257	Current Status of Baricitinib as a Repurposed Therapy for COVID-19. <i>Pharmaceuticals</i> , 2021, 14, 680.	1.7	15
258	The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis. <i>Clinical Epidemiology and Global Health</i> , 2021, 11, 100755.	0.9	32
259	Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 709856.	1.6	23
260	What we learned in the past year in managing our COVID-19 patients in intensive care units?. <i>World Journal of Critical Care Medicine</i> , 2021, 10, 81-101.	0.8	5
261	Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 700502.	1.8	18
262	Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial). <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1010-1020.	1.0	24
263	The Many Faces of JAKs and STATs Within the COVID-19 Storm. <i>Frontiers in Immunology</i> , 2021, 12, 690477.	2.2	18
264	COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now "New Hopes?. <i>Pharmaceuticals</i> , 2021, 14, 664.	1.7	3
265	Secondary pneumonias in critically ill patients with COVID-19: risk factors and outcomes. <i>Current Opinion in Critical Care</i> , 2021, 27, 468-473.	1.6	15
266	Coronavirus disease 2019 vaccination in women seeking pregnancy or in early pregnancy: What is there to debate?. <i>Fertility and Sterility</i> , 2021, 116, 15.	0.5	0
267	Key summary of German national treatment guidance for hospitalized COVID-19 patients. <i>Infection</i> , 2022, 50, 93-106.	2.3	30

#	ARTICLE	IF	CITATIONS
268	Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 3771-3788.	2.5	17
269	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	0.6	53
271	COVID-19 in liver transplant recipients. <i>Journal of Liver Transplantation</i> , 2021, 3, 100026.	0.2	6
272	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. <i>Cell Reports</i> , 2021, 36, 109450.	2.9	38
273	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
274	COVID-19 and Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 328-333.	1.0	7
275	JAK Inhibitors “ More Than Just Glucocorticoids. <i>New England Journal of Medicine</i> , 2021, 385, 463-465.	13.9	15
276	Biomedical Research COVID-19 Impact Assessment: Lessons Learned and Compelling Needs. <i>NAM Perspectives</i> , 2021, 2021, .	1.3	4
277	Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, e41-e45.	0.5	9
278	Immunomodulatory therapy, risk factors and outcomes of hospital-acquired bloodstream infection in patients with severe COVID-19 pneumonia: a Spanish case“control matched multicentre study (BACTCOVID). <i>Clinical Microbiology and Infection</i> , 2021, 27, 1685-1692.	2.8	18
279	Coronavirus disease 2019 in children. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 500-509.	1.3	8
280	Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 787-793.	1.5	31
281	Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	61
282	Impact of the COVID-19 pandemic on the management of chronic noninfectious respiratory diseases. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1035-1048.	1.0	14
283	Myocarditis associated with Covid“19 disease: A systematic review of published case reports and case series. <i>International Journal of Clinical Practice</i> , 2021, 75, e14470.	0.8	55
284	The signal pathways and treatment of cytokine storm in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 255.	7.1	355
285	A signaling pathway-driven bioinformatics pipeline for predicting therapeutics against emerging infectious diseases. <i>F1000Research</i> , 0, 10, 330.	0.8	8
286	Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. <i>Frontiers in Pharmacology</i> , 2021, 12, 699949.	1.6	15

#	ARTICLE	IF	CITATIONS
287	Admission NT-proBNP and outcomes in patients without history of heart failure hospitalized with COVID-19. <i>ESC Heart Failure</i> , 2021, 8, 4278-4287.	1.4	20
288	Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of Inflammatory Cytokines in a Rodent Model. <i>ACS Infectious Diseases</i> , 2021, 7, 2229-2237.	1.8	12
289	Remdesivir for the treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD014962.	1.5	90
290	Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic. <i>Current Treatment Options in Oncology</i> , 2021, 22, 93.	1.3	5
291	Organotypic human ex vivo models for coronavirus disease 2019 research and drug development. <i>Current Opinion in Pharmacology</i> , 2021, 59, 11-18.	1.7	5
292	COVID-19: Inflammatory Profile. <i>Annual Review of Medicine</i> , 2022, 73, 65-80.	5.0	43
293	Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. <i>Clinical Rheumatology</i> , 2021, 40, 4671-4674.	1.0	21
294	COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. <i>Cytokine and Growth Factor Reviews</i> , 2021, 60, 28-45.	3.2	21
295	Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism. <i>Virus Research</i> , 2021, 301, 198464.	1.1	16
296	Clinical Trends Among U.S. Adults Hospitalized With COVID-19, March to December 2020. <i>Annals of Internal Medicine</i> , 2021, 174, 1409-1419.	2.0	45
297	First-in-Class Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1467-1477.	2.3	25
298	Challenges in interpreting cytokine data in COVID-19 affect patient care and management. <i>PLoS Biology</i> , 2021, 19, e3001373.	2.6	7
299	Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19. <i>Clinical and Translational Science</i> , 2021, 14, 2556-2565.	1.5	13
300	Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e157-e157.	0.5	2
301	The "cytokine storm": molecular mechanisms and therapeutic prospects. <i>Trends in Immunology</i> , 2021, 42, 681-705.	2.9	156
302	Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8663.	1.8	18
303	COVID-19 and Effect on Liver Transplant. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 483-499.	0.3	5
305	Remdesivir and Cyclosporine Synergistically Inhibit the Human Coronaviruses OC43 and SARS-CoV-2. <i>Frontiers in Pharmacology</i> , 2021, 12, 706901.	1.6	16



#	ARTICLE	IF	CITATIONS
306	Update on human genetic susceptibility to COVID-19: susceptibility to virus and response. <i>Human Genomics</i> , 2021, 15, 57.	1.4	15
307	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. <i>Journal of Medical Virology</i> , 2021, 93, 6737-6749.	2.5	13
308	Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1151-1158.	2.0	16
309	Antirheumatic drugs and COVID-19: frustrations and hopes. <i>Meditinskiy Sovet</i> , 2021, , 134-139.	0.1	0
310	Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e158-e158.	0.5	3
311	A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity. <i>JCI Insight</i> , 2021, 6, .	2.3	23
312	COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation. <i>Cells</i> , 2021, 10, 2212.	1.8	4
313	Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome. <i>Nature Microbiology</i> , 2021, 6, 1245-1258.	5.9	101
314	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
315	Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges. <i>Frontiers in Microbiology</i> , 2021, 12, 637554.	1.5	8
316	Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 368-380.e3.	1.5	59
317	Evaluation of the Treatment Efficacy and Safety of Remdesivir for COVID-19: a Meta-analysis. <i>SN Comprehensive Clinical Medicine</i> , 2021, , 1-12.	0.3	6
318	Heterocyclic compounds as antiviral drugs: Synthesis, structure-activity relationship and traditional applications. <i>Journal of Heterocyclic Chemistry</i> , 2021, 58, 2226-2260.	1.4	15
319	Elevated inflammatory markers are associated with poor outcomes in COVID-19 patients treated with remdesivir. <i>Journal of Medical Virology</i> , 2022, 94, 384-387.	2.5	14
321	Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. <i>Thorax</i> , 2022, 77, 203-209.	2.7	90
322	The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?. <i>Cytokine</i> , 2021, 144, 155593.	1.4	61
323	Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19. <i>BioScience Trends</i> , 2021, 15, 205-210.	1.1	8
324	Deconstructing the Treatment Effect of Remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1: Implications for Critical Care Resource Utilization. <i>Clinical Infectious Diseases</i> , 2022, 74, 2209-2217.	2.9	11

#	ARTICLE	IF	CITATIONS
325	COVID-19: potential therapeutics for pediatric patients. <i>Pharmacological Reports</i> , 2021, 73, 1520-1538.	1.5	12
326	Ugonin J Acts as a SARS-CoV-2 3C-like Protease Inhibitor and Exhibits Anti-inflammatory Properties. <i>Frontiers in Pharmacology</i> , 2021, 12, 720018.	1.6	11
327	What is the role of remdesivir in patients with COVID-19?. <i>Current Opinion in Critical Care</i> , 2021, 27, 487-492.	1.6	16
328	TYK2 in Cancer Metastases: Genomic and Proteomic Discovery. <i>Cancers</i> , 2021, 13, 4171.	1.7	14
329	A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients. <i>Viruses</i> , 2021, 13, 1706.	1.5	9
330	Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19. <i>Respiratory Investigation</i> , 2021, 59, 799-803.	0.9	24
331	Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-221146.	0.5	4
332	SARS-CoV-2 Treatment: Current Therapeutic Options and the Pursuit of Tailored Therapy. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 7457.	1.3	11
333	Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19. <i>Current Opinion in Critical Care</i> , 2021, 27, 493-496.	1.6	15
334	Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by van Vollenhoven et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e178-e178.	0.5	7
335	The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 933-936.	5.2	80
336	Progress and pitfalls of a year of drug repurposing screens against COVID-19. <i>Current Opinion in Virology</i> , 2021, 49, 183-193.	2.6	25
337	Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020. <i>Drug Safety</i> , 2021, 44, 987-998.	1.4	9
338	Immune System Disequilibrium "Neutrophils, Their Extracellular Traps, and COVID-19-Induced Sepsis. <i>Frontiers in Medicine</i> , 2021, 8, 711397.	1.2	6
339	Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience. , 2021, 3, e0517.		10
340	Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 3784.	1.0	12
341	The case of complement inhibitors. <i>Advances in Biological Regulation</i> , 2021, 81, 100822.	1.4	4
342	NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments. <i>Frontiers in Pharmacology</i> , 2021, 12, 708302.	1.6	37

#	ARTICLE	IF	CITATIONS
343	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. <i>Frontiers in Immunology</i> , 2021, 12, 719023.	2.2	28
344	IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 483.	3.8	31
345	Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study. <i>Arthritis Care and Research</i> , 2021, 73, 1322-1331.	1.5	12
346	Potential Immunomodulatory Properties of Biologically Active Components of Spices Against SARS-CoV-2 and Pan Î <sup>2</sup> -Coronaviruses. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 729622.	1.8	11
347	The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). <i>Leukemia</i> , 2021, 35, 2917-2923.	3.3	16
348	Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 69, 102039.	1.1	33
349	A systematic review on the effects of Echinacea supplementation on cytokine levels: Is there a role in COVID-19?. <i>Metabolism Open</i> , 2021, 11, 100115.	1.4	15
350	Herpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective, Observational Study. <i>Microorganisms</i> , 2021, 9, 1896.	1.6	28
351	Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, eabd0205.	5.6	26
353	Treatment Options for COVID-19-Related Guillain-Barré Syndrome. <i>Neurologist</i> , 2021, 26, 196-224.	0.4	7
354	Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	39
355	In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. <i>PLoS Pathogens</i> , 2021, 17, e1009929.	2.1	108
356	Current status of therapeutic alternatives for COVID-19: A narrative review. <i>Infezioni in Medicina</i> , 2021, 29, 312-327.	0.7	8
357	Effect of mortality from COVID-19 on inpatient outcomes. <i>Journal of Medical Virology</i> , 2022, 94, 318-326.	2.5	9
358	The Binary Model of Chronic Diseases Applied to COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 716084.	2.2	6
359	SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1249-1251.	0.5	6
360	Two Patients With Severe COVID Pneumonia Treated With the Seraph-100 Microbind Affinity Blood Filter. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 1228-1232.	1.3	4
361	A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis. <i>Current Issues in Molecular Biology</i> , 2021, 43, 1212-1225.	1.0	9

#	ARTICLE	IF	CITATIONS
363	Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1349-1351.	5.2	28
364	Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e491-e498.	2.9	34
365	Role of rehabilitation amidst the COVID-19 pandemic: a review. <i>Journal of Translational Medicine</i> , 2021, 19, 376.	1.8	7
366	BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review. <i>Clinical Immunology</i> , 2021, 230, 108816.	1.4	17
367	Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i> -Mutant Diffuse Intrinsic Pontine Glioma. <i>Cancer Discovery</i> , 2022, 12, 416-431.	7.7	25
368	Combination therapies for COVID-19: An overview of the clinical trials landscape. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1590-1597.	1.1	18
370	Microbial Metabolites: The Emerging Hotspot of Antiviral Compounds as Potential Candidates to Avert Viral Pandemic Alike COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 732256.	1.6	15
371	Using informative features in machine learning based method for COVID-19 drug repurposing. <i>Journal of Cheminformatics</i> , 2021, 13, 70.	2.8	21
372	Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS-CoV-2 infection in Taiwan. <i>Internal Medicine Journal</i> , 2021, 51, 1543-1544.	0.5	2
373	Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3296-3302.	1.3	30
374	COVID-19 susceptibility variants associate with blood clots, thrombophlebitis and circulatory diseases. <i>PLoS ONE</i> , 2021, 16, e0256988.	1.1	12
375	Success stories of AI in drug discovery - where do things stand?. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 79-92.	2.5	21
376	Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis. <i>Cell Death and Differentiation</i> , 2022, 29, 420-438.	5.0	14
377	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Public Health</i> , 2021, 9, 729559.	1.3	27
378	Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	26
379	The use of Tofacitinib in the Management of COVID-19 Pneumonia. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 1087-1088.	0.3	0
381	Clinical and laboratory factors associated with coronavirus disease 2019 (Covid-19): A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2021, 31, e2288.	3.9	13
382	Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1407-1418.	5.2	501

#	ARTICLE	IF	CITATIONS
383	A hitchhiker's guide through the COVID-19 galaxy. <i>Clinical Immunology</i> , 2021, 232, 108849.	1.4	3
384	Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19. <i>Pharmaceuticals</i> , 2021, 14, 955.	1.7	12
385	Immune-mediated inflammatory disease therapeutics: past, present and future. <i>Nature Reviews Immunology</i> , 2021, 21, 680-686.	10.6	106
386	Emergency drug use in a pandemic: Harsh lessons from COVID-19. <i>Cell</i> , 2021, 184, 5497-5500.	13.5	2
387	Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 425-434.	2.0	27
388	Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far. <i>Biologics</i> , 2021, 1, 252-284.	2.3	11
389	Emerging and Established Histological Techniques for the Analysis of Thrombosis in COVID-19 Lungs. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 745906.	1.1	1
390	COVID-19 infection after mRNA 1273 vaccine: review of the most frequently asked questions. <i>Infezioni in Medicina</i> , 2021, 29, 305-311.	0.7	2
391	Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro. <i>Pharmaceuticals</i> , 2021, 13, 1400.	2.0	35
392	Scientific evidence in the COVID-19 treatment: A comprehensive review. <i>World Journal of Virology</i> , 2021, 10, 217-228.	1.3	6
393	SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway. <i>Journal of Virology</i> , 2021, 95, e0086221.	1.5	58
394	Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 4019.	1.0	11
396	COVID-19 An update on oral symptoms, newer variants, second wave and vaccination drive in India â€” A Review. <i>International Journal of Oral Health Dentistry</i> , 2021, 7, 155-160.	0.0	0
397	Prompt Reduction in CRP, IL-6, IFN- $\gamma$ , IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 734838.	1.2	13
398	Tofacitinib Associated with Reduced Intubation Rates in the Management of Severe COVID-19 Pneumonia: A Preliminary Experience. <i>Indian Journal of Critical Care Medicine</i> , 2022, 25, 1108-1112.	0.3	8
399	Repurposing Cardio-Metabolic Drugs to Fight Covid19. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 419-423.	1.0	1
401	Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?. <i>Current Opinion in Virology</i> , 2021, 50, 119-127.	2.6	32
402	Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. <i>Frontiers in Immunology</i> , 2021, 12, 752227.	2.2	25

#	ARTICLE	IF	CITATIONS
403	Coronavirus disease-2019: A review on the disease exacerbation via cytokine storm and concurrent management. <i>International Immunopharmacology</i> , 2021, 99, 108049.	1.7	13
404	Impact of COVID-19 on Pediatric Immunocompromised Patients. <i>Pediatric Clinics of North America</i> , 2021, 68, 1029-1054.	0.9	16
405	Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>International Immunopharmacology</i> , 2021, 99, 108027.	1.7	22
406	Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. <i>Pharmacological Research</i> , 2021, 173, 105848.	3.1	16
407	Management of Coronavirus Disease 2019 (COVID-19) Pneumonia. , 2022, , 342-349.		4
408	Ongoing trials on COVID-19 treatments: please, don't forget Venous Thromboembolism!. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1170-1171.	1.0	0
409	Remdesivir " Current evidence & perspective in management of COVID-19 infection. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 1808.	0.3	5
410	Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4684-4701.	1.9	27
411	COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. <i>Infectious Diseases and Therapy</i> , 2021, 10, 93-113.	1.8	13
412	Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2. <i>Paediatric Drugs</i> , 2021, 23, 119-129.	1.3	62
413	COVID-19 Antiviral and Treatment Candidates: Current Status. <i>Immune Network</i> , 2021, 21, e7.	1.6	8
414	SARS-CoV-2 therapeutics: how far do we stand from a remedy?. <i>Pharmacological Reports</i> , 2021, 73, 750-768.	1.5	17
415	Treatment Approach, Pharmacological Agents and Vaccines. , 2021, , 145-162.		0
416	New Scoring System for Predicting Mortality in Patients with COVID-19. <i>Yonsei Medical Journal</i> , 2021, 62, 806.	0.9	10
417	SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 817-819.	0.5	37
418	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. <i>Emerging Microbes and Infections</i> , 2021, 10, 507-535.	3.0	202
419	Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords. <i>Clinical Infectious Diseases</i> , 2022, 74, 1686-1690.	2.9	3
424	Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. <i>Viruses</i> , 2021, 13, 29.	1.5	118

#	ARTICLE	IF	CITATIONS
425	Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition. <i>Cleveland Clinic Journal of Medicine</i> , 2021, , .	0.6	8
426	Newer medications in coronavirus disease-2019 (COVID-19) infection. <i>Assam Journal of Internal Medicine</i> , 2021, 11, 1.	0.0	0
427	Mouse Models for the Study of SARS-CoV-2 Infection. <i>Comparative Medicine</i> , 2021, 71, 383-397.	0.4	11
429	Enfermedad por coronavirus 2019 (COVID-19). <i>Medicina UPB</i> , 2021, 40, 41-49.	0.1	0
430	Anti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia. <i>Clinical Critical Care</i> , 2021, , .	0.0	0
431	Antiviral therapy and immunotherapy of COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 53-59.	0.5	0
432	Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States. <i>Clinical Therapeutics</i> , 2021, 43, 1877-1893.e4.	1.1	6
433	Utility of conventional clinical risk scores in a low-risk COVID-19 cohort. <i>BMC Infectious Diseases</i> , 2021, 21, 1094.	1.3	6
434	The use of antiviral drugs in children. <i>Journal of Chemotherapy</i> , 2022, 34, 73-86.	0.7	0
435	The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section. <i>Journal of Infection and Public Health</i> , 2022, 15, 142-151.	1.9	10
436	Overview of potential drugs for the treatment of new coronavirus Infection (COVID-19). <i>Acta Biomedica Scientifica</i> , 2021, 6, 74-86.	0.1	0
437	Integrating heterogeneous data to facilitate COVID-19 drug repurposing. <i>Drug Discovery Today</i> , 2022, 27, 558-566.	3.2	17
438	Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. <i>Cardiology in Review</i> , 2022, 30, 145-157.	0.6	11
439	Activation of STAT3 signaling pathway in the kidney of COVID-19 patients. <i>Journal of Nephrology</i> , 2022, 35, 735-743.	0.9	10
440	Mortality risk factors of COVID-19 infection in kidney transplantation recipients: a systematic review and meta-analysis of cohorts and clinical registries. <i>Scientific Reports</i> , 2021, 11, 20073.	1.6	40
441	Immunotherapy in the Treatment of COVID-19. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2021, 20, 158-168.	0.1	0
442	Transient leukocytopenia following combination therapy for COVID-19. <i>Respiratory Investigation</i> , 2021, 60, 158-158.	0.9	3
443	Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. <i>Seminars in Immunology</i> , 2021, 55, 101508.	2.7	37

#	ARTICLE	IF	CITATIONS
445	Potential interactions between antineoplastic agents and medicines used to treat Covid-19. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110404.	0.5	2
446	Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 206-210.	0.8	4
447	Inpatient Hospital Costs for COVID-19 Patients in the United States. <i>Advances in Therapy</i> , 2021, 38, 5557-5595.	1.3	74
449	Host genetic factors determining COVID-19 susceptibility and severity. <i>EBioMedicine</i> , 2021, 72, 103629.	2.7	126
450	Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 99-104.	1.4	8
451	Personalized therapy: can it tame the COVID-19 monster?. <i>Personalized Medicine</i> , 2021, 18, 583-593.	0.8	4
452	COVID-19 Therapy: the Role of Antirheumatic Drugs. <i>Antibiotiki I Khimioterapiya</i> , 2021, 66, 83-89.	0.1	0
453	Association of Serum Ferritin Levels and Methylprednisolone Treatment With Outcomes in Nonintubated Patients With Severe COVID-19 Pneumonia. <i>JAMA Network Open</i> , 2021, 4, e2127172.	2.8	10
454	COVID-19 survivors with calcineurin-inhibitors-treated rheumatoid arthritis. <i>Modern Rheumatology Case Reports</i> , 2021, , .	0.3	1
455	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1365-1376.	5.2	119
456	Mechanisms of Immunothrombosis by SARS-CoV-2. <i>Biomolecules</i> , 2021, 11, 1550.	1.8	11
457	Glucocorticoid Dose in COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1801.	3.8	8
458	Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection. <i>Physiology</i> , 2022, 37, 88-100.	1.6	18
459	Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 585-609.	2.0	5
460	COVID-19 Advanced Care. <i>Journal of Personalized Medicine</i> , 2021, 11, 1082.	1.1	1
461	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1419-1426.	5.2	123
462	Coronavirus disease 2019 in liver transplant patients: Clinical and therapeutic aspects. <i>World Journal of Hepatology</i> , 2021, 13, 1299-1315.	0.8	1
463	Drugs and liver injury: a not to be overlooked binomial in COVID-19. <i>Journal of Chemotherapy</i> , 2022, 34, 207-220.	0.7	3



#	ARTICLE	IF	CITATIONS
464	JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 911-925.	1.5	57
465	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 34-40.	0.5	26
466	Remdesivir: Quo vadis?. <i>Biochemical Pharmacology</i> , 2021, 193, 114800.	2.0	17
467	A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition. <i>Antiviral Research</i> , 2021, 195, 105183.	1.9	8
468	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112276.	2.5	9
469	Myeloid cells in COVID-19 microenvironment. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 372.	7.1	14
470	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. <i>Infectious Diseases and Therapy</i> , 2021, , 1.	1.8	6
471	Immune interventions in COVID-19: a matter of time?. <i>Mucosal Immunology</i> , 2022, 15, 198-210.	2.7	14
472	Prolonged corticosteroid therapy and cytomegalovirus infection in patients with severe COVID-19. <i>Journal of Medical Virology</i> , 2022, 94, 1067-1073.	2.5	12
473	Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling. <i>Drug Discovery Today</i> , 2022, 27, 390-400.	3.2	22
474	Drug-Repositioning Approaches Based on Medical and Life Science Databases. <i>Frontiers in Pharmacology</i> , 2021, 12, 752174.	1.6	8
475	Targeting Macrophage Dysregulation for Viral Infections: Novel Targets for Immunomodulators. <i>Frontiers in Immunology</i> , 2021, 12, 768695.	2.2	7
476	A retrospective analysis of 902 hospitalized COVID-19 patients in Lebanon: clinical epidemiology and risk factors. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100048.	0.4	6
480	Pharmacotherapy of COVID-19: Considerations for Pregnancy and Breastfeeding. <i>Journal of Obstetrics, Gynecology and Cancer Research</i> , 2022, 7, 1-6.	0.0	1
481	COVID-19 and antimicrobial resistance: A cross-study. <i>Science of the Total Environment</i> , 2022, 807, 150873.	3.9	79
482	Evidence of the Clinical Efficacy of Antiviral Agents against SARS-CoV-2. <i>International Journal of Pharmaceutical Research and Allied Sciences</i> , 2021, 10, 94-111.	0.1	2
483	Remdesivir, the magic bullet for COVID-19?. <i>Journal of the Pediatrics Association of India</i> , 2020, 9, 96.	0.0	1
484	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86

#	ARTICLE	IF	CITATIONS
485	Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 749657.	1.2	13
486	Host-modifying drugs against COVID-19: some successes, but not yet the breakthrough. <i>Environmental Microbiology</i> , 2021, 23, 7257-7270.	1.8	0
487	Clinical Practice in COVID-19: the most frequently asked questions to Infectious Diseases Specialists. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101648.	0.3	1
488	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	1.8	21
489	Myeloid dysregulation and therapeutic intervention in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101524.	2.7	9
490	Mortality in Solid Organ Transplant Recipients Hospitalized for Covid-19. <i>American Journal of Transplantation</i> , 2021, 22, 12.	2.6	4
491	Identification and Development of Therapeutics for COVID-19. <i>MSystems</i> , 2021, 6, e0023321.	1.7	20
492	Janus kinase inhibitors for hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 773-779.	2.0	8
493	Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11711.	1.2	10
494	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021, 7, .	1.8	6
495	Thermodynamic and structural insights into the repurposing of drugs that bind to SARS-CoV-2 main protease. <i>Molecular Systems Design and Engineering</i> , 2022, 7, 123-131.	1.7	5
496	Implementation of platform trials in the COVID-19 pandemic: A rapid review. <i>Contemporary Clinical Trials</i> , 2022, 112, 106625.	0.8	26
497	Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease. <i>Internal Medicine</i> , 2022, 61, 585-589.	0.3	8
498	Host cell-intrinsic innate immune recognition of SARS-CoV-2. <i>Current Opinion in Virology</i> , 2022, 52, 30-38.	2.6	32
499	Cardiovascular complications after COVID-19 in chronic kidney disease, dialysis and kidney transplant patients. <i>International Urology and Nephrology</i> , 2022, 54, 1551-1563.	0.6	5
500	The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. <i>Frontiers in Pharmacology</i> , 2021, 12, 704205.	1.6	89
501	Nimotuzumab for COVID-19: case series. <i>Immunotherapy</i> , 2022, 14, 185-193.	1.0	6
504	IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study. <i>Cardiology Journal</i> , 2022, 29, 140-147.	0.5	9

#	ARTICLE	IF	CITATIONS
505	Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review. <i>International Journal of General Medicine</i> , 2021, Volume 14, 8557-8571.	0.8	33
506	Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment. <i>Egyptian Heart Journal</i> , 2021, 73, 103.	0.4	0
507	Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients. <i>International Journal of Nephrology</i> , 2021, 2021, 1-9.	0.7	8
508	Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2022, 94, 1523-1534.	2.5	28
509	A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	46
510	COVID-19 in Children. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 1-14.	1.9	10
511	Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Infectious Diseases and Therapy</i> , 2022, 11, 231-248.	1.8	15
512	Gene Expression Risk Scores for COVID-19 Illness Severity. <i>Journal of Infectious Diseases</i> , 2023, 227, 322-331.	1.9	4
513	Comparative Safety and Efficacy of Remdesivir Versus Remdesivir Plus Convalescent Plasma Therapy (CPT) and the Effect of Timing of Initiation of Remdesivir in COVID-19 Patients: An Observational Study From North East India. <i>Cureus</i> , 2021, 13, e19976.	0.2	2
514	Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients. <i>Healthcare (Switzerland)</i> , 2021, 9, 1575.	1.0	20
515	Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study. <i>Advances in Therapy</i> , 2021, , 1.	1.3	8
516	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. <i>Journal of Virology</i> , 2022, 96, JVI0155121.	1.5	18
517	Common points of therapeutic intervention in COVID-19 and in allogeneic hematopoietic stem cell transplantation associated severe cytokine release syndrome. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2021, 68, 240-255.	0.4	2
518	The paradox of immunosuppressants and COVID-19. <i>European Respiratory Journal</i> , 2022, 59, 2102828.	3.1	8
519	JAK-STAT Pathway: A Novel Target to Tackle Viral Infections. <i>Viruses</i> , 2021, 13, 2379.	1.5	38
520	Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example. <i>Translational Psychiatry</i> , 2021, 11, 591.	2.4	7
521	SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 766-775.	2.9	117
522	Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. <i>Hepatology Communications</i> , 2022, 6, 255-269.	2.0	41

#	ARTICLE	IF	CITATIONS
523	Model-Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 Pandemic. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 572-578.	2.3	7
524	Coronavirus Disease 2019: Clinics, Treatment, and Prevention. <i>Frontiers in Microbiology</i> , 2021, 12, 761887.	1.5	21
525	COVID-19 and Cardiovascular System. Part 3. COVID-19 Current Treatment Approaches: Evidence-Based Review. <i>Sklifosovsky Journal Emergency Medical Care</i> , 2021, 10, 438-451.	0.3	0
526	Discovery of Diverse Natural Products as Inhibitors of SARS-CoV-2 M <sup>pro</sup> Protease through Virtual Screening. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 6094-6106.	2.5	14
527	Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection. <i>Molecular Biology Reports</i> , 2022, 49, 827-831.	1.0	4
528	Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5366.	1.0	4
529	Treatments for COVID-19: Lessons from 2020 and new therapeutic options. <i>Current Opinion in Pharmacology</i> , 2022, 62, 43-59.	1.7	23
531	Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. <i>Lancet Rheumatology</i> , The, 2022, 4, e33-e41.	2.2	96
532	Is Ventilator-Associated Pneumonia More Frequent in Patients With Coronavirus Disease 2019?. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, .	0.4	5
533	The JAK/STAT signaling pathway: from bench to clinic. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 402.	7.1	636
534	A Clinical Update on Employing Tocilizumab to Fight COVID-19. , 0, , .		0
535	Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19). <i>Drugs and Aging</i> , 2021, 38, 1067-1074.	1.3	11
536	Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. <i>Translational Research</i> , 2022, 241, 83-95.	2.2	12
537	Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (September 2021). <i>Acute Medicine &amp; Surgery</i> , 2021, 8, e706.	0.5	16
538	Nascent perspectives on COVID-19 treatments. <i>Side Effects of Drugs Annual</i> , 2021, 43, 329-335.	0.6	0
541	Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112614.	2.5	5
542	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021, 7, e001896.	1.8	22
543	The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness. <i>Monaldi Archives for Chest Disease</i> , 2022, , .	0.3	2

#	ARTICLE	IF	CITATIONS
544	COVID-19 Disease and Dermatomyositis: A Mini-Review. <i>Frontiers in Immunology</i> , 2021, 12, 747116.	2.2	24
545	A review of COVID-19 therapeutics in pregnancy and lactation. <i>Obstetric Medicine</i> , 2022, 15, 225-232.	0.5	13
547	Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective. <i>Molecules</i> , 2022, 27, 658.	1.7	24
548	Potential therapeutic options for COVID-19: an update on current evidence. <i>European Journal of Medical Research</i> , 2022, 27, 6.	0.9	85
549	Cross-species virus transmission and its pandemic potential. <i>Bulletin of the National Research Centre</i> , 2022, 46, 18.	0.7	5
551	COVID-19: Les thérapeutiques. , 2022, 1, 13-13.		0
552	Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations. <i>Cells</i> , 2022, 11, 306.	1.8	15
553	Therapeutic role of immunomodulators during the COVID-19 pandemic – a narrative review. <i>Postgraduate Medicine</i> , 2022, 134, 160-179.	0.9	9
554	Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19. <i>SN Comprehensive Clinical Medicine</i> , 2022, 4, 42.	0.3	5
555	Immune-Guided Therapy of COVID-19. <i>Cancer Immunology Research</i> , 2022, 10, 384-402.	1.6	20
556	Baricitinib: Two Birds with One Stone. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, , 1-2.	0.3	1
557	Innate immunological pathways in COVID-19 pathogenesis. <i>Science Immunology</i> , 2022, 7, eabm5505.	5.6	101
558	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. <i>International Journal of Biological Sciences</i> , 2022, 18, 459-472.	2.6	65
559	First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy. <i>BMJ Open</i> , 2022, 12, e054069.	0.8	13
560	Remdesivir + ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106542.	1.1	7
561	Pulmonary Aspects of COVID-19. <i>Annual Review of Medicine</i> , 2022, 73, 81-93.	5.0	8
562	Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. <i>Medicina (Lithuania)</i> , 2022, 58, 144.	0.8	126
563	Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection. <i>Inflammopharmacology</i> , 2022, 30, 23-49.	1.9	8

#	ARTICLE	IF	CITATIONS
564	Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. <i>Nature Reviews Rheumatology</i> , 2022, 18, 133-145.	3.5	193
565	COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference. <i>Antiviral Research</i> , 2022, 197, 105227.	1.9	19
566	Elimination of Aicardi-Goutières syndrome protein SAMHD1 activates cellular innate immunity and suppresses SARS-CoV-2 replication. <i>Journal of Biological Chemistry</i> , 2022, 298, 101635.	1.6	9
567	Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 558.	1.7	6
568	Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan. <i>CEN Case Reports</i> , 2022, , 1.	0.5	4
569	JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present). <i>Expert Opinion on Therapeutic Patents</i> , 2022, 32, 225-242.	2.4	12
570	Risk Factors for Therapeutic Intervention of Remdesivir in Mild to Moderate COVID-19 – A Single-Center Retrospective Study of the COVID-19 Fourth Pandemic Period in Wakayama, Japan. <i>Medicina (Lithuania)</i> , 2022, 58, 118.	0.8	3
571	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
572	Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS). <i>Journal of Gastroenterology</i> , 2022, 57, 174-184.	2.3	8
573	Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. <i>BMC Infectious Diseases</i> , 2022, 22, 107.	1.3	63
574	Impaired JAK-STAT pathway signaling in leukocytes of the frail elderly. <i>Immunity and Ageing</i> , 2022, 19, 5.	1.8	6
575	A guide to immunotherapy for COVID-19. <i>Nature Medicine</i> , 2022, 28, 39-50.	15.2	206
576	The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 800492.	1.2	20
577	Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. , 2022, 1, .		77
578	Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 824-837.	1.9	49
579	Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches. <i>BMB Reports</i> , 2022, 55, 11-19.	1.1	7
580	Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19. <i>Clinical Therapeutics</i> , 2022, 44, 364-373.	1.1	22
581	Advances in clinical outcomes: What we have learned during the COVID-19 pandemic. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 569-578.	1.5	3

#	ARTICLE	IF	CITATIONS
582	Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19). Expert Opinion on Pharmacotherapy, 2022, 23, 623-628.	0.9	5
583	Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis. Antiviral Research, 2022, 198, 105247.	1.9	39
586	COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus. Infectious Disease Clinics of North America, 2022, 36, 397-421.	1.9	7
587	Innate immunity: the first line of defense against SARS-CoV-2. Nature Immunology, 2022, 23, 165-176.	7.0	303
588	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 2022, 185, 916-938.e58.	13.5	164
589	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Annals of Medicine, 2022, 54, 524-540.	1.5	225
590	Spatiotemporal Adaptations of Macrophage and Dendritic Cell Development and Function. Annual Review of Immunology, 2022, 40, 525-557.	9.5	27
591	New drugs under development for COPD. Minerva Medica, 2022, 113, .	0.3	14
592	Therapeutics for COVID-19 and post COVID-19 complications: An update. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100086.	1.7	55
593	Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine, the, 2022, 10, 327-336.	5.2	131
594	Pharmacologic Treatment and Management of Coronavirus Disease 2019. Infectious Disease Clinics of North America, 2022, 36, 349-364.	1.9	2
595	Baricitinib for patients with severe COVID-19â€”time to change the standard of care?. Lancet Respiratory Medicine, the, 2022, , .	5.2	6
596	Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. Open Forum Infectious Diseases, 2022, 9, ofac043.	0.4	4
597	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€”CoVâ€”2 and Hyperinflammation in Pediatric COVIDâ€”19: Version 3. Arthritis and Rheumatology, 2022, 74, .	2.9	146
598	Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy. Respiratory Investigation, 2022, 60, 248-255.	0.9	12
599	COVID-19 and arrhythmia: An overview. Journal of Cardiology, 2022, 79, 468-475.	0.8	21
600	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. Current Infectious Disease Reports, 2021, 23, 28.	1.3	5
601	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infectious Diseases, The, 2022, 22, 622-635.	4.6	135

#	ARTICLE	IF	CITATIONS
602	The state of complement in COVID-19. <i>Nature Reviews Immunology</i> , 2022, 22, 77-84.	10.6	159
603	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab588.	0.4	7
604	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. <i>MBio</i> , 2021, 12, e0334721.	1.8	45
605	A Case Report: Genetically Distinct Severe Acute Respiratory Syndrome Coronavirus-2 Variant Causing Reinfection. <i>Frontiers in Microbiology</i> , 2021, 12, 792514.	1.5	2
606	Pharmacological treatment of COVID-19: an opinion paper. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 115-130.	0.5	47
609	Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882210816.	1.4	10
610	COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e13.	1.6	12
611	Educational Impact of #IDJClub, a Twitter-Based Infectious Diseases Journal Club. <i>Clinical Infectious Diseases</i> , 2022, 74, S244-S250.	2.9	7
612	Monoclonal antibody therapies in the management of SARS-CoV-2 infection. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 41-58.	1.9	26
613	Combination drug delivery approaches for viral infections. , 2022, , 129-147.		0
614	Current therapeutic choices for coronavirus disease 2019: a state-of-the-art review. , 2022, , 79-93.		0
615	Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. <i>Alexander Saltanov Intensive Care Herald</i> , 2022, , 5-140.	0.2	7
616	COVID-19 and lung involvement. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 189-211.	0.1	0
617	Promotion of proper use of anti-SARS-CoV-2 drugs and SARS-CoV-2 vaccines by hospital pharmacists and establishment of an adverse drug reaction reporting system. <i>Global Health &amp; Medicine</i> , 2022, 4, 137-140.	0.6	0
618	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. <i>Nature Reviews Rheumatology</i> , 2022, 18, 191-204.	3.5	105
619	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	1.2	9
620	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13763.	1.7	5
621	The role of ferroptosis in acute lung injury. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 1453-1461.	1.4	19



#	ARTICLE	IF	CITATIONS
623	A Retrospective Observational Cohort Study on the Efficacy and Safety of Methylprednisolone Pulse Therapy for COVID-19 Pneumonia. <i>Covid</i> , 2022, 2, 244-253.	0.7	2
624	Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. <i>Antiviral Therapy</i> , 2022, 27, 135965352210827.	0.6	10
625	Adrenomedullin Therapy in Moderate to Severe COVID-19. <i>Biomedicines</i> , 2022, 10, 533.	1.4	8
626	Emerging small molecule antivirals may fit neatly into COVID-19 treatment. <i>Drugs and Therapy Perspectives</i> , 2022, 38, 112-126.	0.3	12
627	Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop. <i>Vaccine</i> , 2022, 40, 3484-3489.	1.7	6
628	Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study. <i>BMJ Open</i> , 2022, 12, e055137.	0.8	6
629	Targeting ectromelia virus and TNF/NF- $\kappa$ B or STAT3 signaling for effective treatment of viral pneumonia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	11
630	Tocilizumab and COVID-19: Timing of Administration and Efficacy. <i>Frontiers in Pharmacology</i> , 2022, 13, 825749.	1.6	27
631	Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2. <i>Clinical and Experimental Nephrology</i> , 2022, 26, 476.	0.7	2
632	Predicting Impact of Prone Position on Oxygenation in Mechanically Ventilated Patients with COVID-19. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 883-889.	1.3	7
634	Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. <i>Frontiers in Medicine</i> , 2022, 9, 849222.	1.2	2
635	Specialized interferon action in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	56
636	Ofelecin i mi Vlaplinâ€™Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. <i>Medicina (Lithuania)</i> , 2022, 58, 309.	0.8	4
637	The Current Role for Biologic Medications in the Treatment of Pediatric COVID-19 and MIS-C. <i>Pediatric Annals</i> , 2022, 51, e57-e62.	0.3	0
638	Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling. <i>Frontiers in Immunology</i> , 2022, 13, 795315.	2.2	35
639	Targeting Mononuclear Phagocytes to Treat COVID-19. , 0, , .		0
640	What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?. <i>Frontiers in Microbiology</i> , 2022, 13, 843587.	1.5	1
641	Review of Anti-inflammatory and Anti-viral therapeutics for hospitalized patients infected with SARS-CoV-2. <i>Critical Care Clinics</i> , 2022, , .	1.0	3

#	ARTICLE	IF	CITATIONS
642	Efficacy, Safety of Baricitinib plus Remdesivir versus Standard Therapy (Remdesivir) in Patients with Severe COVID-19 Infection in Third Wave of Epidemics in Myanmar: Case Control Study. <i>International Journal of Medical Science and Clinical Research Studies</i> , 2022, 02, .	0.0	0
643	Successful treatment of generalized granuloma annulare with baricitinib. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	9
644	Cellular therapies for the treatment and prevention of SARS-CoV-2 infection. <i>Blood</i> , 2022, 140, 208-221.	0.6	13
645	Photodynamic disinfection of SARS-CoV-2 clinical samples using a methylene blue formulation. <i>Photochemical and Photobiological Sciences</i> , 2022, 21, 1101-1109.	1.6	18
646	Neuroimmune disorders in COVID-19. <i>Journal of Neurology</i> , 2022, 269, 2827-2839.	1.8	27
647	COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response. <i>Acta Haematologica</i> , 2022, 145, 297-309.	0.7	7
648	Case Report: Severe Acute Pulmonary COVID-19 in a Teenager Post Autologous Hematopoietic Stem Cell Transplant. <i>Frontiers in Pediatrics</i> , 2022, 10, 809061.	0.9	3
649	Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 611-621.	4.6	22
650	Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Rheumatology</i> , The, 2022, 4, e351-e361.	2.2	24
651	Statin use in hospitalized patients with COVID-19: A comprehensive analysis of the New York City Public Hospital System. <i>American Journal of Medicine</i> , 2022, , .	0.6	2
652	COVID-19 Cardiovascular Connection: A Review of Cardiac Manifestations in COVID-19 Infection and Treatment Modalities. <i>Current Problems in Cardiology</i> , 2022, , 101186.	1.1	7
653	No perfect therapy for the imperfect COVID-19 cytokine storm. <i>Lancet Rheumatology</i> , The, 2022, 4, e308-e310.	2.2	7
654	Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. <i>Rheumatology</i> , 2022, 61, SI151-SI156.	0.9	7
655	BridgeDPI: a novel Graph Neural Network for predicting drug-protein interactions. <i>Bioinformatics</i> , 2022, 38, 2571-2578.	1.8	31
656	Probable treatment options for Covid-19: A brief review. <i>IP International Journal of Comprehensive and Advanced Pharmacology</i> , 2022, 7, 17-26.	0.1	0
657	Can anti-parasitic drugs help control COVID-19?. <i>Future Virology</i> , 2022, 17, 315-339.	0.9	5
658	Real World Impact of Remdesivir and Dexamethasone on Clinical Outcomes of Severe Coronavirus Disease 2019 in a Community Hospital. <i>Military Medicine</i> , 2023, 188, e1529-e1533.	0.4	3
659	Drug dosing in hospitalized obese patients with COVID-19. <i>Critical Care</i> , 2022, 26, 60.	2.5	3

#	ARTICLE	IF	CITATIONS
660	Herpes zoster meningitis in a rheumatoid arthritis patient treated with tofacitinib. <i>BMJ Case Reports</i> , 2022, 15, e247276.	0.2	2
661	Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia. <i>BMC Infectious Diseases</i> , 2022, 22, 254.	1.3	3
662	Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection. <i>Frontiers in Pharmacology</i> , 2022, 13, 849095.	1.6	5
663	Co-Administration of Menstrual Blood-Derived Stem Cells and Remdesivir for the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Induced Pneumonia: A Research Protocol. , 2022, 6, 1-12.		1
664	Neuroimmunology and Neurological Manifestations of COVID-19. , 0, , .		0
665	Distinguishing immune activation and inflammatory signatures of multisystem inflammatory syndrome in children (MIS-C) versus hemophagocytic lymphohistiocytosis (HLH). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1592-1606.e16.	1.5	24
666	Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment. <i>Immunotherapy</i> , 2022, 14, 521-530.	1.0	17
667	Efficacy of early use of remdesivir: a systematic review of subgroup analysis. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 249-259.	0.5	3
668	Shedding of SARS-CoV-2 for 85 Days in COVID-19 Patients With Type 2 Diabetes Mellitus and Lung Metastasis: A Case Report. <i>Frontiers in Medicine</i> , 2022, 9, 828819.	1.2	0
670	Prediction of the need for intensive oxygen supplementation during hospitalisation among subjects with COVID-19 admitted to an academic health system in Texas: a retrospective cohort study and multivariable regression model. <i>BMJ Open</i> , 2022, 12, e058238.	0.8	3
671	Atorvastatin Effectively Inhibits Ancestral and Two Emerging Variants of SARS-CoV-2 in vitro. <i>Frontiers in Microbiology</i> , 2022, 13, 721103.	1.5	11
672	Application of Baricitinib in Dermatology. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1935-1941.	1.6	10
673	A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. <i>Pathogens</i> , 2022, 11, 368.	1.2	23
676	The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19. <i>JAMA Network Open</i> , 2022, 5, e222973.	2.8	16
677	COVID-19 FAQs in Pediatric Cardiac Surgery: 2022 Perspective and Updates. <i>World Journal for Pediatric &amp; Congenital Heart Surgery</i> , 2022, , 215013512210859.	0.3	1
678	Management of hepatitis B virus reactivation due to treatment of COVID-19. <i>Hepatology International</i> , 2022, 16, 257-268.	1.9	17
679	COVID-19-associated <i>Cryptococcus</i> infection (CACI): a review of literature and clinical pearls. <i>Infection</i> , 2022, 50, 1007-1012.	2.3	19
680	CD24Fc: an emerging COVID-19 therapy. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 565-567.	4.6	4

#	ARTICLE	IF	CITATIONS
681	The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010220.	1.3	11
682	Current challenges in different approaches to control COVID-19: a comprehensive review. <i>Bulletin of the National Research Centre</i> , 2022, 46, 47.	0.7	4
683	Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study. <i>Scientific Reports</i> , 2022, 12, 5323.	1.6	7
684	REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	1
685	COVID-19 Trials: Who Participates and Who Benefits?. <i>Southern Medical Journal</i> , 2022, 115, 256-261.	0.3	2
686	COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib: A Case Report. <i>Cureus</i> , 2022, 14, e23755.	0.2	1
687	High-cited favorable studies for COVID-19 treatments ineffective in large trials. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 1-9.	2.4	4
688	COVID-19 therapeutics: Challenges and directions for the future. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119893119.	3.3	92
689	Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 871592.	2.2	3
690	Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group. <i>EClinicalMedicine</i> , 2022, 46, 101362.	3.2	20
691	Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going. <i>Drugs in Context</i> , 2022, 11, 1-17.	1.0	12
692	Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105254.	1.0	21
695	Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study. <i>F1000Research</i> , 0, 11, 400.	0.8	1
696	Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial. <i>Critical Care</i> , 2022, 26, 101.	2.5	19
697	Potential plants for inflammatory dysfunction in the SARS-CoV-2 infection. <i>Inflammopharmacology</i> , 2022, 30, 749-773.	1.9	3
698	Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study. <i>Medicina (Lithuania)</i> , 2022, 58, 513.	0.8	16
699	Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study. <i>Respiratory Medicine and Research</i> , 2022, 81, 100903.	0.4	3
700	B3O3 monolayer with dual application in sensing of COVID-19 biomarkers and drug delivery for treatment purposes: A periodic DFT study. <i>Journal of Molecular Liquids</i> , 2022, 354, 118855.	2.3	19

#	ARTICLE	IF	CITATIONS
701	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. <i>Pharmacological Research</i> , 2022, 179, 106201.	3.1	23
702	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. <i>American Journal of Emergency Medicine</i> , 2022, 56, 158-170.	0.7	13
703	Why we still need drugs for COVID-19 and can't just rely on vaccines. <i>Respirology</i> , 2022, 27, 109-111.	1.3	8
704	Interplay of Nutrition and Psychoneuroendocrine-immune Modulation: Relevance for COVID-19 in BRICS Nations. <i>Frontiers in Microbiology</i> , 2021, 12, 769884.	1.5	3
705	Use of Baricitinib in Combination With Remdesivir and Steroid in COVID-19 Treatment: A Multicenter Retrospective Study. <i>Cureus</i> , 2021, 13, e20620.	0.2	3
706	Acute Respiratory Distress Syndrome and COVID-19: A Literature Review. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 7225-7242.	1.6	15
707	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. <i>World Journal of Hepatology</i> , 2021, 13, 1850-1874.	0.8	10
708	SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease. <i>PLoS ONE</i> , 2021, 16, e0261656.	1.1	16
709	Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies. <i>Pharmaceuticals</i> , 2022, 15, 48.	1.7	16
710	Predicting 90-day survival of patients with COVID-19: Survival of Severely Ill COVID (SOSIC) scores. <i>Annals of Intensive Care</i> , 2021, 11, 170.	2.2	11
711	Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 763687.	1.8	3
712	Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 3391-3404.	0.4	3
714	Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges. <i>PLoS Pathogens</i> , 2021, 17, e1010106.	2.1	12
715	Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. <i>Cells</i> , 2022, 11, 52.	1.8	11
716	Computational Study of the Therapeutic Potential of Novel Heterocyclic Derivatives against SARS-CoV-2. <i>Covid</i> , 2021, 1, 757-774.	0.7	7
717	Clinical trials during the COVID-19 pandemic: research design and lessons. , 2021, , 214-231.		0
718	Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab581.	0.4	16
719	Recent insights into COVID-19 in children and clinical recommendations. <i>Current Pediatric Reviews</i> , 2021, 17, .	0.4	2

#	ARTICLE	IF	CITATIONS
720	Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 1277.	1.3	8
722	Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks. <i>JAMA Cardiology</i> , 2022, 7, 450.	3.0	17
723	Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists. <i>Pharmaceuticals</i> , 2021, 14, 1256.	1.7	10
724	Safety of conventional immunosuppressive therapies for patients with dermatological conditions and coronavirus disease 2019: A review of current evidence. <i>Journal of Dermatology</i> , 2022, 49, 317-329.	0.6	3
726	Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection. <i>Infection</i> , 2022, 50, 295-308.	2.3	19
728	The infection risks of JAK inhibition. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 253-261.	1.3	21
729	SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases. <i>Journal of Translational Autoimmunity</i> , 2022, 5, 100154.	2.0	12
730	Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease. <i>Scientific Reports</i> , 2022, 12, 4925.	1.6	21
731	Dysregulation of the leukocyte signaling landscape during acute COVID-19. <i>PLoS ONE</i> , 2022, 17, e0264979.	1.1	4
732	Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients. <i>Journal of Fungi (Basel)</i> , Tj ETQq1 1 0.784314 rgBT /Overlock 10 1.5 11		
733	The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: An observational study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1635-1641.	1.1	2
734	Outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1029-1032.	0.8	4
735	Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Frontiers in Medicine</i> , 2022, 9, 844728.	1.2	13
736	Bacterial Ventilator-Associated Pneumonia in COVID-19 Patients: Data from the Second and Third Waves of the Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 2279.	1.0	13
738	COVID-19: Some unresolved issues. <i>Revista Espanola De Quimioterapia</i> , 2022, , .	0.5	1
739	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment. <i>Process Biochemistry</i> , 2022, 118, 154-170.	1.8	4
740	Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022). <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 399-419.	1.0	1
741	SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. <i>Inflammation</i> , 2022, 45, 1430-1449.	1.7	16

#	ARTICLE	IF	CITATIONS
742	JAK inhibitors and COVID-19. , 2022, 10, e002838.		34
743	Postdischarge Evaluation for Individuals Hospitalized with COVID-19. Southern Medical Journal, 2022, 115, 13-17.	0.3	0
744	Antiviral and anti-inflammatory drugs to combat COVID-19: Effects on cardiac ion channels and risk of ventricular arrhythmias.. BiolImpacts, 2022, 12, 9-20.	0.7	4
746	Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches.. BMB Reports, 2021, , .	1.1	0
747	Clinical update on the use of mesenchymal stem cells in COVID-19.. American Journal of Translational Research (discontinued), 2021, 13, 12195-12205.	0.0	1
748	What's JAK'ing Up the Risk of Cancer and Thromboembolism?. , 2022, 19, .		0
750	Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice. Zoological Research, 2022, 43, 457-468.	0.9	3
751	Therapeutics in the Treatment of COVID-19 for Children and Adolescents. Pediatric Infection and Vaccine, 2022, 29, 1.	0.1	2
752	Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates. Molecules, 2022, 27, 2723.	1.7	29
753	Unravelling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. Open Forum Infectious Diseases, 0, , .	0.4	1
754	pcMSC Modulates Immune Dysregulation in Patients With COVID-19-Induced Refractory Acute Lung Injury. Frontiers in Immunology, 2022, 13, 871828.	2.2	2
755	Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm. International Journal of Molecular Sciences, 2022, 23, 4545.	1.8	11
756	Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. Value in Health, 2022, , .	0.1	5
757	Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update. Clinical Immunology, 2022, 239, 109022.	1.4	12
758	Drug discovery strategies for drug repositioning based on data science. Okayama Igakkai Zasshi, 2022, 134, 16-21.	0.0	0
759	Treatment of COVID-19 in a Patient With Maple Syrup Urine Disease. Cureus, 2022, , .	0.2	0
760	Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review. Audiology Research, 2022, 12, 224-248.	0.8	6
761	Development of Azaindole-Based Frameworks as Potential Antiviral Agents and Their Future Perspectives. Journal of Medicinal Chemistry, 2022, 65, 6454-6495.	2.9	13

#	ARTICLE	IF	CITATIONS
762	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). <i>Leukemia</i> , 2022, 36, 1467-1480.	3.3	63
763	Treatment strategies of Covid-19. A rheumatology perspective.. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	3
764	Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study. , 2022, 4, e0702.		10
766	Pharmacological and non-pharmacological strategies in coronavirus disease 2019: A literature review. <i>Annals of Medicine and Surgery</i> , 2022, 77, 103709.	0.5	0
767	What is the full potential of baricitinib in treating patients with COVID-19?. <i>Expert Review of Clinical Immunology</i> , 2022, , 1-5.	1.3	2
768	Year in Review 2021: Noteworthy Literature in Cardiothoracic Critical Care. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2022, , 108925322211006.	0.4	1
769	A Comprehensive Overview of Globally Approved JAK Inhibitors. <i>Pharmaceutics</i> , 2022, 14, 1001.	2.0	83
771	High mortality in patients with active malignancy and severe COVID-19. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 153-160.	0.3	2
772	Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
773	COVID-19â€™from emerging global threat to ongoing pandemic crisis. <i>Baylor University Medical Center Proceedings</i> , 2022, 35, 468-475.	0.2	4
774	Tofacitinib Therapy for Alopecia Areata is not Associated with Adverse Events during COVID-19 Infection. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	0.6	0
775	<scp>Prepared to Act: Lessons Learned by the Special Pathogens Research Network, Based on Collaborations with the NIAID-Led Adaptive COVID-19 <scp>Treatment Trial</scp>. <i>Health Security</i> , 2022, , .	0.9	2
776	Contributions of the Regional Emerging Special Pathogen Treatment Centers to the US COVID-19 Pandemic Response. <i>Health Security</i> , 2022, 20, S-4-S-12.	0.9	4
777	COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication. <i>Current Medical Research and Opinion</i> , 2022, 38, 1071-1079.	0.9	5
778	Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 131-148.	0.2	5
779	Compounds co-targeting kinases in axon regulatory pathways promote regeneration and behavioral recovery after spinal cord injury in mice. <i>Experimental Neurology</i> , 2022, 355, 114117.	2.0	6
780	Antidiabetic Drugs and their Potential Use in COVID-19: A Mechanistic Approach. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, .	0.6	0
781	Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?. <i>Pharmaceutics</i> , 2022, 15, 616.	1.7	7



#	ARTICLE	IF	CITATIONS
782	Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules. Trends in Pharmacological Sciences, 2022, 43, 866-881.	4.0	13
783	Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein. Scientific Reports, 2022, 12, 8108.	1.6	13
784	ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection. Science Immunology, 2022, 7, eabo6294.	5.6	82
785	Human Identical Sequences, hyaluronan, and hymecromone – the new mechanism and management of COVID-19. Molecular Biomedicine, 2022, 3, 15.	1.7	4
786	Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade. World Journal of Virology, 2022, 11, 113-128.	1.3	5
787	Comments on COVID-19 and AL Amyloidosis, the Missing Links. American Journal of Medicine, 2022, 135, e137-e138.	0.6	1
788	Pearson's patterns correlational of clinical risks at admissions with hospitalization outcomes during initial COVID-19 outbreak. IScience, 2022, 25, 104415.	1.9	1
789	Addition of Baricitinib to COVID-19 Treatment Does Not Increase Bacterial Infection Compared to Standard Therapy: A Single-center Retrospective Study. Internal Medicine, 2022, 61, 2273-2279.	0.3	3
790	Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone. Frontiers in Pharmacology, 0, 13, .	1.6	8
791	Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy. Viruses, 2022, 14, 1197.	1.5	8
792	COVID-19-Current Therapeutical Approaches and Future Perspectives. Processes, 2022, 10, 1053.	1.3	1
794	Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respiratory Medicine, the, 2022, 10, 888-899.	5.2	62
795	Discovery of new drug indications for COVID-19: A drug repurposing approach. PLoS ONE, 2022, 17, e0267095.	1.1	6
796	Comparison of COVID-19 Induced Respiratory Failure and Typical ARDS: Similarities and Differences. Frontiers in Medicine, 2022, 9, .	1.2	22
797	Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes. Cell Reports, 2022, 39, 110945.	2.9	12
798	Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2. ImmunoTargets and Therapy, 0, Volume 11, 23-35.	2.7	3
799	Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients. Current Transplantation Reports, 2022, 9, 185-198.	0.9	3
800	<sc>TNF</sc> – <sc>IFN</sc> synergy amplifies senescence-associated inflammation and <sc>SARS-CoV</sc> receptor expression via hyperactivated <sc>JAK</sc>/<sc>STAT1</sc>. Aging Cell, 2022, 21, .	3.0	31

#	ARTICLE	IF	CITATIONS
801	SARS-CoV-2 RNA copy number is a factor associated with the mortality of COVID-19 and improves the predictive performance of mortality in severe cases.. Japanese Journal of Infectious Diseases, 2022, , .	0.5	0
802	An Approach to the Treatment of Children With COVID-19. Pediatric Infectious Disease Journal, 2022, 41, 654-662.	1.1	5
803	Neutrophils in COVID-19: Not Innocent Bystanders. Frontiers in Immunology, 2022, 13, .	2.2	52
804	Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment. Frontiers in Pharmacology, 2022, 13, .	1.6	0
805	Baricitinib as the treatment of choice for hospitalised individuals with COVID-19. EClinicalMedicine, 2022, 49, 101493.	3.2	5
806	Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials. EClinicalMedicine, 2022, 49, 101489.	3.2	52
808	COVID-19 and its impact on cancer, HIV, and mentally ill patients. , 2022, , 95-137.		1
809	Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19â€”Results From a Pilot Open-Label, Randomized Controlled Trial. Frontiers in Pharmacology, 0, 13, .	1.6	27
810	Immune system changes in those with hypertension when infected with SARS-CoV-2. Cellular Immunology, 2022, 378, 104562.	1.4	2
811	Comparative evaluation of authorized drugs for treating Covidâ€“19 patients. Health Science Reports, 2022, 5, .	0.6	30
812	Key Advances in Intensive Care and the Coronavirus Disease-19 Research and Practice Boost. Journal of Clinical Medicine, 2022, 11, 3370.	1.0	0
814	New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 284-308.	1.4	9
815	The Impacts of COVID-19 on Musculoskeletal Health. Current Osteoporosis Reports, 2022, 20, 213-225.	1.5	11
816	Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies. Antiviral Research, 2022, 204, 105367.	1.9	17
817	The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19. Vaccines, 2022, 10, 951.	2.1	8
818	Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. Journal of Pharmaceutical Sciences, 2022, 111, 2652-2661.	1.6	15
819	Death and invasive mechanical ventilation risk in hospitalized COVID-19 patients treated with anti-SARS-CoV-2 monoclonal antibodies and/or antiviral agents: A systematic review and network meta-analysis protocol. PLoS ONE, 2022, 17, e0270196.	1.1	3
820	Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis. Scientific Reports, 2022, 12, .	1.6	21

#	ARTICLE	IF	CITATIONS
821	Contemporary Concise Review 2021: <scp>COVID</scp> and other respiratory infections. <i>Respirology</i> , 0, , .	1.3	1
822	Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. <i>BioNanoScience</i> , 2022, 12, 1436-1454.	1.5	2
823	Outcomes of Heart Failure in COVID-19 Patients: An Appalachian Experience. <i>Cardiology Research</i> , 2022, 13, 162-171.	0.5	2
824	Janus kinase inhibitors for the treatment of COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	22
825	A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection. <i>Infectious Disease Reports</i> , 2022, 14, 446-452.	1.5	8
826	Investigation of target sequencing of SARS-CoV-2 and immunogenic GWAS profiling in host cells of COVID-19 in Vietnam. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	2
827	COVID-19 coagulopathy “ what should we treat?. <i>Experimental Physiology</i> , 2022, 107, 749-758.	0.9	8
828	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	28
830	Host-directed immunotherapy of viral and bacterial infections: past, present and future. <i>Nature Reviews Immunology</i> , 2023, 23, 121-133.	10.6	71
831	Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19. <i>IScience</i> , 2022, 25, 104612.	1.9	9
832	Emergency myelopoiesis in critical illness: lessons from the COVID-19 pandemic. <i>Irish Journal of Medical Science</i> , 2023, 192, 831-832.	0.8	4
833	Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. <i>PLoS Pathogens</i> , 2022, 18, e1010547.	2.1	12
835	Urine metabolomics links dysregulation of the tryptophan-kynurenine pathway to inflammation and severity of COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	18
836	Drug-“Membrane Interactions: Effects of Virus-Specific RNA-Dependent RNA Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers. <i>Biochemistry</i> , 2022, 61, 1392-1403.	1.2	5
837	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2022, 60, 2200803.	3.1	22
838	Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. <i>Pharmaceuticals</i> , 2022, 15, 739.	1.7	6
839	Liposome encapsulated clodronate mediated elimination of pathogenic macrophages and microglia: A promising pharmacological regime to defuse cytokine storm in COVID-19. <i>Medicine in Drug Discovery</i> , 2022, 15, 100136.	2.3	6
840	Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19. , 2022, , 21-63.		0

#	ARTICLE	IF	CITATIONS
841	Bionanomaterials for diagnosis and therapy of SARS-CoV-2. , 2022, , 469-489.		0
842	COVID Coagulopathy and Thrombosis: A Systematic Review. Touch Reviews in Oncology & Haematology, 2022, 18, 78.	0.1	2
843	Currently available drugs for the treatment of Coronavirus-2. , 2022, , 77-95.		0
844	Artificial intelligence methods to repurpose and discover new drugs to fight the Coronavirus disease-2019 pandemic. , 2022, , 537-557.		0
845	Thyroid Function During and After COVID-19 Infection: A Review. , 2022, 18, 58.		6
846	The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens. Npj Digital Medicine, 2022, 5, .	5.7	11
847	Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents. Clinical and Experimental Pediatrics, 2022, 65, 377-386.	0.9	5
848	How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. Blood, 2022, 140, 673-684.	0.6	20
849	The Impact of Key Secular Trends During the first Three Waves the COVID-19 Pandemic. Annals of Epidemiology, 2022, , .	0.9	2
850	Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial. Clinical Infectious Diseases, 2023, 76, e216-e226.	2.9	15
851	Acute severe hepatitis of unknown origin in children: considerations from the perspective of immunology. World Journal of Pediatrics, 2022, 18, 529-532.	0.8	9
852	Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19. Scientific Reports, 2022, 12, .	1.6	25
853	Current Effective Therapeutics in Management of COVID-19. Journal of Clinical Medicine, 2022, 11, 3838.	1.0	23
854	Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus. International Journal of Molecular Sciences, 2022, 23, 7702.	1.8	2
855	Comparison of Cell Fusions Induced by Influenza Virus and SARS-CoV-2. International Journal of Molecular Sciences, 2022, 23, 7365.	1.8	2
856	Use of Tox21 Screening Data to Evaluate the COVID-19 Drug Candidates for Their Potential Toxic Effects and Related Pathways. Frontiers in Pharmacology, 0, 13, .	1.6	6
857	Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats. Annals of Surgery, 2023, 278, e137-e146.	2.1	6
858	Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity. Molecular Biomedicine, 2022, 3, .	1.7	1

#	ARTICLE	IF	CITATIONS
859	Recent clinical findings on the role of kinase inhibitors in COVID-19 management. <i>Life Sciences</i> , 2022, 306, 120809.	2.0	10
860	Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis. , 2022, 1, .		16
861	Binding Adaptation of GS-441524 Diversifies Macro Domains and Downregulates SARS-CoV-2 de-MARylation Capacity. <i>Journal of Molecular Biology</i> , 2022, 434, 167720.	2.0	6
862	Management of Severe and Critical COVID-19 Infection with Immunotherapies. <i>Infectious Disease Clinics of North America</i> , 2022, , .	1.9	0
863	Pharmacy students' knowledge and confidence of COVID-19 following an interactive didactic class. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 1082-1087.	0.5	3
864	Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 269-297.	0.8	2
865	A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-8.	0.7	2
866	Drug-Target Network Study Reveals the Core Target-Protein Interactions of Various COVID-19 Treatments. <i>Genes</i> , 2022, 13, 1210.	1.0	0
867	JAK inhibition as a new treatment strategy for patients with COVID-19. <i>Biochemical Pharmacology</i> , 2022, 202, 115162.	2.0	10
868	Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8845.	1.2	9
869	Efficacy and safety of baricitinib for the treatment of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2022, 49, 1139-1149.	0.9	5
870	Outcomes of COVID-19 in a Large Cohort of Lung Transplant Recipients: A Retrospective Study. <i>Transplantation</i> , 2022, 3, 257-266.	0.3	1
871	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	1.8	46
872	Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	27
873	Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113459.	2.5	6
874	Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 187-209.	1.0	5
875	Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	6
876	Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality. <i>Lancet</i> , The, 2022, 400, 338-339.	6.3	4

#	ARTICLE	IF	CITATIONS
877	Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. <i>Lancet, The</i> , 2022, 400, 359-368.	6.3	146
878	Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, e116-e125.	2.9	13
879	Gut-brain communication in COVID-19: molecular mechanisms, mediators, biomarkers, and therapeutics. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 947-960.	1.3	8
880	Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2023, 29, 13-21.	2.8	19
881	Role of tocilizumab therapy in COVID-19 patients: a systematic review and meta-analysis. <i>International Journal of Research in Medical Sciences</i> , 2022, 10, 1730.	0.0	0
882	The role of interleukin-22 in lung health and its therapeutic potential for COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
883	Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. <i>Journal of Clinical Medicine</i> , 2022, 11, 4464.	1.0	13
884	Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	15
885	Thymosin $\alpha$ 1 for COVID-19: Look before You Leap!. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 892-893.	0.3	0
886	Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. <i>MedComm</i> , 2022, 3, .	3.1	17
888	Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection. <i>International Immunopharmacology</i> , 2022, 112, 109183.	1.7	26
889	Effects of mild obesity on outcomes in Japanese patients with COVID-19: a nationwide consortium to investigate COVID-19 host genetics. <i>Nutrition and Diabetes</i> , 2022, 12, .	1.5	10
890	Neuro-Axonal Damage and Alteration of Blood-Brain Barrier Integrity in COVID-19 Patients. <i>Cells</i> , 2022, 11, 2480.	1.8	15
892	The Low Expression of Fc-Gamma Receptor III (CD16) and High Expression of Fc-Gamma Receptor I (CD64) on Neutrophil Granulocytes Mark Severe COVID-19 Pneumonia. <i>Diagnostics</i> , 2022, 12, 2010.	1.3	1
894	Role of tannic acid against SARS-cov-2 cell entry by targeting the interface region between S-protein-RBD and human ACE2. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
895	The Pharmacist's Role in Managing COVID-19 in Chronic Kidney Disease Patients: A Review of Existing Strategies and Future Implications. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 94.	0.6	1
896	Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients. <i>Transfusion</i> , 2022, 62, 1997-2011.	0.8	7
897	Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9297.	1.8	4

#	ARTICLE	IF	CITATIONS
898	Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols. <i>Inflammopharmacology</i> , 0, , .	1.9	3
899	Care of the Seriously Ill Patient with SARS CoV-2. <i>Medical Clinics of North America</i> , 2022, , .	1.1	1
900	Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States. <i>Advances in Therapy</i> , 2022, 39, 4723-4741.	1.3	1
901	Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-13.	0.7	5
902	Immunomodulatory therapies for COVID-19. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
903	COVID-19 metabolism: Mechanisms and therapeutic targets. <i>MedComm</i> , 2022, 3, .	3.1	15
904	Therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients with moderate to severe COVID-19 pneumonia: a systematic review and meta-analysis. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 1109-1132.	1.0	4
905	Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-6.	0.7	4
906	Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814.	1.8	47
907	A review of clinical efficacy data supporting emergency use authorization for <scp>COVID</scp> -19 therapeutics and lessons for future pandemics. <i>Clinical and Translational Science</i> , 0, , .	1.5	2
908	Synthesis and Biological Evaluation of Umifenovir Analogues as Anti-SARS-CoV-2 Agents. <i>ChemistrySelect</i> , 2022, 7, .	0.7	3
909	Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19. <i>Journal of Inflammation Research</i> , 0, Volume 15, 4907-4920.	1.6	5
910	Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1742-1749.	0.5	26
911	Oral Janus kinase inhibitors for treating hospitalized patients with COVID-19: An updated systematic review and meta-analysis of randomized controlled trials. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, , .	1.5	1
912	Aromatic or Hetero-aromatic Directly Attached Tri and Tetrasubstituted Methanes: New Chemical Entities as Anti-infectives. <i>Current Medicinal Chemistry</i> , 2022, 29, .	1.2	0
913	Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101375.	0.7	0
914	The Characteristics of Patients with Severe COVID-19 Pneumonia Treated with Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber Column (PMX-DHP). <i>Infection and Drug Resistance</i> , 0, Volume 15, 4819-4828.	1.1	0
915	Clinical prediction models in hospitalized patients with COVID-19: A multicenter cohort study. <i>Respiratory Medicine</i> , 2022, 202, 106954.	1.3	6

#	ARTICLE	IF	CITATIONS
916	Central nervous system manifestations of monogenic autoinflammatory disorders and the neurotropic features of SARS-CoV-2: Drawing the parallels. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	2
917	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. <i>International Immunopharmacology</i> , 2022, 111, 109161.	1.7	9
918	Severe coronavirus disease 2019 in a patient with TAFRO syndrome: A case report. <i>Clinical Infection in Practice</i> , 2022, 16, 100158.	0.2	2
919	Clinical impact of clonal hematopoiesis on severe COVID-19 patients without canonical risk factors. <i>Haematologica</i> , 2023, 108, 257-260.	1.7	1
920	Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	16
921	Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001332.	1.2	7
922	Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. <i>Lancet</i> , The, 2022, 400, 1145-1156.	6.3	129
923	The landscape of potential health benefits of carotenoids as natural supportive therapeutics in protecting against Coronavirus infection. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113625.	2.5	4
924	Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis. <i>Respiratory Medicine</i> , 2022, 202, 106986.	1.3	6
925	COVID-19 in patients with B cell immune deficiency. <i>Journal of Immunological Methods</i> , 2022, 510, 113351.	0.6	1
926	Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2022, 16, 117954842211193.	0.5	5
927	COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
928	Remdesivir Treatment in Moderately Ill COVID-19 Patients: A Retrospective Single Center Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 5066.	1.0	5
929	Strategies for Cardio-Oncology Care During the COVID-19 Pandemic. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2022, 24, 137-153.	0.4	2
930	Perspective: repurposed Drugs for COVID-19. <i>Archives of Medical Science</i> , 2022, 18, 1378-1391.	0.4	3
931	COVID-19: Opportunities to Improve Prognosis. <i>Herald of the Russian Academy of Sciences</i> , 2022, 92, 404-411.	0.2	1
932	Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice. <i>ACS Omega</i> , 2022, 7, 31935-31944.	1.6	11
934	The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19. <i>Annals of Internal Medicine</i> , 2022, 175, 1401-1410.	2.0	32



#	ARTICLE	IF	CITATIONS
935	A novel logical model of COVID-19 intracellular infection to support therapies development. PLoS Computational Biology, 2022, 18, e1010443.	1.5	0
936	COVID-19-Related ARDS: Key Mechanistic Features and Treatments. Journal of Clinical Medicine, 2022, 11, 4896.	1.0	15
937	COVID-19 and Kidney Transplantation. Nephrology Self-assessment Program: NephSAP, 2022, 21, 238-245.	3.0	0
938	Investigating and Resolving Cardiotoxicity Induced by COVID-19 Treatments using Human Pluripotent Stem Cell-Derived Cardiomyocytes and Engineered Heart Tissues. Advanced Science, 2022, 9, .	5.6	11
939	Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials. Frontiers in Pharmacology, 0, 13, .	1.6	8
941	Complement C5a inhibition: a new form of COVID-19 treatment for mechanically ventilated patients?. Lancet Respiratory Medicine, the, 2022, 10, 1103-1104.	5.2	2
942	Safety and effectiveness of RBD-specific polyclonal equine F(ab <sup>2</sup> ) fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study. PLoS ONE, 2022, 17, e0274796.	1.1	0
944	Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review. Cureus, 2022, , .	0.2	2
945	Management of COVID-19: A comprehensive and practical approach. Medical Journal Armed Forces India, 2022, , .	0.3	1
946	Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). Transplantation and Cellular Therapy, 2022, 28, 810-821.	0.6	9
947	Transcriptomic clustering of critically ill COVID-19 patients. European Respiratory Journal, 2023, 61, 2200592.	3.1	8
948	SARS-CoV-2 Variant Surveillance in Genomic Medicine Era. Infectious Diseases, 0, , .	4.0	0
950	Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2022, 23, 11058.	1.8	2
951	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021-2022. Jammi, 2022, 7, 163-169.	0.3	0
952	A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19. Advances in Therapy, 2022, 39, 4910-4960.	1.3	28
953	COVID-19 Therapies for inpatients: a review and quality assessment of clinical guidelines. ERJ Open Research, 0, , 00236-2022.	1.1	2
954	Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review. Life, 2022, 12, 1472.	1.1	6
955	Significant Publications on Infectious Diseases Pharmacotherapy in 2021. Journal of Pharmacy Practice, 2024, 37, 198-211.	0.5	1

#	ARTICLE	IF	CITATIONS
956	Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis. <i>Journal of Chemotherapy</i> , 2023, 35, 383-396.	0.7	5
957	Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19. <i>Science Immunology</i> , 2022, 7, .	5.6	32
958	COVID-19 immunopathology: From acute diseases to chronic sequelae. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	24
959	Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
962	Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19. <i>ChemMedChem</i> , 2022, 17, .	1.6	33
963	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 995-1015.	1.9	4
964	Multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS. <i>PLoS Pathogens</i> , 2022, 18, e1010819.	2.1	17
965	Recent advances in small-molecular therapeutics for COVID-19. <i>Precision Clinical Medicine</i> , 2022, 5, .	1.3	9
966	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 0, , .	2.9	82
967	Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce. <i>Medical Journal of Australia</i> , 2022, 217, 368-378.	0.8	8
969	SARS-CoV-2 in immunocompromised individuals. <i>Immunity</i> , 2022, 55, 1779-1798.	6.6	50
970	Single-cell co-expression analysis using computational machine learning reveals oxidative, immunopathologic, and myocardial responses for multi-organ failure in COVID-19. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	0
972	Revisiting potential value of antitumor drugs in the treatment of COVID-19. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	1
973	Managing Covid-19 in patients with heart failure: current status and future prospects. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 807-828.	0.6	0
974	An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1695-1700.	0.9	1
975	Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer. <i>Molecular Cancer</i> , 2022, 21, .	7.9	13
976	Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (July 2022). <i>Acute Medicine &amp; Surgery</i> , 2022, 9, .	0.5	6
977	Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211327.	1.0	3

#	ARTICLE	IF	CITATIONS
978	Insights gained from single-cell analysis of immune cells in tofacitinib treatment of Vogt-Koyanagi-Harada disease. JCI Insight, 2022, 7, .	2.3	3
979	In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. Antiviral Research, 2022, 208, 105450.	1.9	13
980	From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?. Biomedicines, 2022, 10, 2620.	1.4	6
981	Infectious side effects of baricitinib: A big data analysis based on VigiBase. Autoimmunity Reviews, 2022, , 103215.	2.5	0
982	COVID-19 Induces Cytokine Storm and Dysfunctional Hemostasis. Current Drug Targets, 2022, 23, 1603-1610.	1.0	3
983	SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. Hematological Oncology, 2023, 41, 128-138.	0.8	6
984	A Review of Potential Therapeutic Strategies for COVID-19. Viruses, 2022, 14, 2346.	1.5	3
985	Baricitinib in the Treatment of COVID-19. , 0, , .		0
986	Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	7
987	Timing of tofacitinib therapy is critical to improving outcomes in severe-critical COVID-19 infection: A retrospective study from a tertiary care hospital. Medicine (United States), 2022, 101, e30975.	0.4	2
988	Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study. International Journal of Infectious Diseases, 2022, 125, 233-240.	1.5	4
989	Sarcoidosis and COVID-19: At the Cross-Road between Immunopathology and Clinical Manifestation. Biomedicines, 2022, 10, 2525.	1.4	10
990	COVID-19: ACT trials for colchicine and antithrombotic therapies. Lancet Respiratory Medicine,the, 2022, 10, 1106-1108.	5.2	1
991	COVID-19 and Gut Injury. Nutrients, 2022, 14, 4409.	1.7	8
992	Randomized Phase 3 Trial of Ruxolitinib for COVID-19-associated Acute Respiratory Distress Syndrome*. Critical Care Medicine, 2022, 50, 1701-1713.	0.4	16
993	Cytokine Storm Syndrome. Annual Review of Medicine, 2023, 74, 321-337.	5.0	32
994	Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. Infectious Diseases and Therapy, 2022, 11, 2159-2176.	1.8	3
995	Management of Axial Spondyloarthritis - Insights into Upadacitinib. Drug Design, Development and Therapy, 0, Volume 16, 3609-3620.	2.0	2

#	ARTICLE	IF	CITATIONS
996	Treatment of severe COVID-19: an evolving paradigm. Expert Opinion on Pharmacotherapy, 2022, 23, 1887-1891.	0.9	5
997	Immune Modulation in Sepsis, ARDS, and Covid-19 " The Road Traveled and the Road Ahead. , 2022, 1, .		6
998	Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities. Vaccines, 2022, 10, 1673.	2.1	1
999	CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. PLoS Pathogens, 2022, 18, e1010479.	2.1	15
1000	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. Frontiers in Pharmacology, 0, 13, .	1.6	8
1001	Therapeutic advances in COVID-19. Nature Reviews Nephrology, 2023, 19, 38-52.	4.1	67
1002	Fluid restriction management in the treatment of COVID-19: a single-center observational study. Scientific Reports, 2022, 12, .	1.6	0
1003	Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. Clinical Microbiology and Infection, 2023, 29, 372-378.	2.8	24
1004	Transient Leukopenia Induced by Combination Therapy for Severe SARS-CoV-2 Pneumonia. European Journal of Case Reports in Internal Medicine, 0, , .	0.2	1
1005	Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19. Annals of Pharmacotherapy, 2023, 57, 769-775.	0.9	8
1006	Evaluating Risk: Benefit Ratio of Fat-Soluble Vitamin Supplementation to SARS-CoV-2-Infected Autoimmune and Cancer Patients: Do Vitamin"Drug Interactions Exist?. Life, 2022, 12, 1654.	1.1	1
1007	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. Life, 2022, 12, 1758.	1.1	9
1008	Postexposure"vaccine"prophylaxis against COVID"19. Journal of Medical Virology, 2023, 95, .	2.5	2
1009	Cytokine Release Syndrome and Sepsis. Infectious Disease Clinics of North America, 2022, 36, 735-748.	1.9	4
1010	Molecular modeling studies of fused pyrimidine derivatives at various receptors. , 2023, , 273-332.		1
1011	Conventional and Kampo Medicine Treatment for Mild-to-moderate COVID-19: A Multicenter, Retrospective, Observational Study by the Integrative Management in Japan for Epidemic Disease (IMJEDI) Tj ETQq 1b30.78434 4 rgBT		0
1012	FDA approved five-membered ring fused pyrimidine-based derivatives and their biological properties. , 2023, , 117-164.		0
1013	AI for Drug Repurposing in the Pandemic Response. , 2022, , 59-84.		0

#	ARTICLE	IF	CITATIONS
1014	The Metabolomics of Critical Illness. Handbook of Experimental Pharmacology, 2022, , .	0.9	0
1015	V. Current Treatment Approach for COVID-19. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 2374-2382.	0.0	0
1016	Acute Ischaemic Stroke in a COVID-19 Patient on Baricitinib - A Causal Effect or a Multifactorial Relationship?. Asian Journal of University Education, 0, 8, 21-24.	0.1	0
1019	DÃ©jÃ© vu all over again? Monkeypox and the urgent need for randomised controlled trials. Lancet Infectious Diseases, The, 2022, , .	4.6	6
1020	Thrombotic storm in coronavirus disease 2019: from underlying mechanisms to its management. Journal of Medical Microbiology, 2022, 71, .	0.7	3
1021	Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial. Molecular Medicine, 2022, 28, .	1.9	7
1022	Virtual screening based on the structure of more than 105 compounds against four key proteins of SARS-CoV-2: MPro, SRBD, RdRp, and PLpro. Informatics in Medicine Unlocked, 2022, 35, 101134.	1.9	3
1023	Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?. Biomedicines, 2022, 10, 2815.	1.4	3
1024	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2022. Journal of Cardiothoracic and Vascular Anesthesia, 2022, , .	0.6	0
1025	Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice. International Journal of Molecular Sciences, 2022, 23, 13478.	1.8	3
1026	A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury. Kidney International, 2023, 103, 514-528.	2.6	11
1027	The Potential Protective Role of GS-441524, a Metabolite of the Prodrug Remdesivir, in Vaccine Breakthrough SARS-CoV-2 Infections. Intensive Care Research, 0, , .	0.2	0
1028	Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. Platelets, 2023, 34, .	1.1	13
1029	Design, Synthesis, and Biological Evaluation of Novel Ruxolitinib and Baricitinib Analogues for Potential Use Against COVID-19. Chemical Biology and Drug Design, 0, , .	1.5	2
1031	Immunomodulators in Mechanically Ventilated Patients With COVID-19: Lessons Learned From Underpowered Trials*. Critical Care Medicine, 2022, 50, 1821-1828.	0.4	1
1032	Human Coronaviruses. , 2023, , 1167-1175.e6.		0
1033	Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier. Antiviral Research, 2023, 209, 105475.	1.9	12
1034	Changing Features of Liver Injury in COVID-19 Patients: Impact of Infection with the SARS-CoV-2 Delta (B.1.617.2) Variants. Infection and Chemotherapy, 2022, 54, 744.	1.0	2

#	ARTICLE	IF	CITATIONS
1035	How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea. Journal of Korean Medical Science, 2022, 37, .	1.1	4
1036	Immune-Targeted Therapies for COVID-19. , 2022, , 451-468.		0
1037	Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns. Journal of Research in Medical Sciences, 2022, 27, 92.	0.4	0
1038	Severe Coronavirus disease (COVID)-19: from pathogenesis to therapy. Shock, 0, Publish Ahead of Print, .	1.0	0
1039	Coronavirus Disease-2019 in the Immunocompromised Host. Clinics in Chest Medicine, 2023, 44, 395-406.	0.8	5
1040	Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis. Frontiers in Medicine, 0, 9, .	1.2	1
1041	Genetics, structure, transmission, epidemiology, immune response, and vaccine efficacies of the SARS-CoV-2 Delta variant: A comprehensive review. Reviews in Medical Virology, 0, , .	3.9	0
1042	Could treatment with immunomodulatory agents targeting IL-1, IL-6, or JAK signalling improve outcomes in patients with severe influenza pneumonia? A systematic and narrative review. HRB Open Research, 0, 5, 77.	0.3	1
1043	The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies. International Journal of Molecular Sciences, 2022, 23, 14914.	1.8	5
1044	Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. Journal of Translational Medicine, 2022, 20, .	1.8	29
1045	Antiviral Treatment of COVID-19 Pneumonia. Clinics in Chest Medicine, 2022, , .	0.8	0
1046	Infliximab as a potential treatment for COVID-19. Expert Review of Anti-Infective Therapy, 2023, 21, 1-5.	2.0	4
1047	Immunomodulatory agents for COVID-19 pneumonia. Clinics in Chest Medicine, 2022, , .	0.8	1
1048	N-acetylcysteine Reduces Inflammasome Activation Induced by SARS-CoV-2 Proteins In Vitro. International Journal of Molecular Sciences, 2022, 23, 14518.	1.8	11
1049	SARS-CoV-2 Infection and COVID-19 in Children. Clinics in Chest Medicine, 2023, 44, 359-371.	0.8	6
1050	Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice. International Journal of Molecular Sciences, 2022, 23, 15027.	1.8	2
1051	Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. Annals of Internal Medicine, 2022, 175, 1716-1727.	2.0	2
1052	A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19. Antimicrobial Agents and Chemotherapy, 2023, 67, .	1.4	10

#	ARTICLE	IF	CITATIONS
1053	Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	17
1054	Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2242918.	2.8	2
1055	COVID-19 Drug Development: Role of Drug Repurposing. , 0, , .		0
1056	Small molecules in the treatment of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	42
1057	Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence. <i>Nature Communications</i> , 2022, 13, .	5.8	13
1059	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118.	1.3	2
1060	Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1061	Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-15.	0.8	7
1062	Management of Coronavirus Disease-2019 Infection in Pregnancy. <i>Emergency Medicine Clinics of North America</i> , 2023, 41, 307-322.	0.5	0
1063	Identification of two specific transcriptomic clusters of COVID-19 ARDS patients with different immune profiles and different outcomes. <i>European Respiratory Journal</i> , 0, , 2202008.	3.1	0
1064	Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation. <i>Health Research Policy and Systems</i> , 2022, 20, .	1.1	3
1065	Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	20
1066	Immune-based therapy for hospitalized patients with COVID-19 and risk of secondary infections: A systematic review and meta-analysis. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	1
1067	Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. <i>International Journal of Infectious Diseases</i> , 2023, 128, 223-229.	1.5	7
1068	Gaps and opportunities in sepsis translational research. <i>EBioMedicine</i> , 2022, 86, 104387.	2.7	6
1070	HIV and COVID-19 Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 035-049.	0.8	2
1071	Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trial. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4
1072	Learning how to treat coronavirus disease 2019 in hematopoietic stem cell transplant patients. <i>Transplant Infectious Disease</i> , 2023, 25, .	0.7	0

#	ARTICLE	IF	CITATIONS
1073	Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
1074	COVID-19: A Comprehensive Review on Cardiovascular Alterations, Immunity, and Therapeutics in Older Adults. <i>Journal of Clinical Medicine</i> , 2023, 12, 488.	1.0	5
1075	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. <i>PLoS Pathogens</i> , 2023, 19, e1011063.	2.1	7
1076	Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19. <i>Science Advances</i> , 2023, 9, .	4.7	6
1077	A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia. <i>Inflammation and Regeneration</i> , 2023, 43, .	1.5	8
1078	Surgeonsâ€™ involvement in COVID-19 treatment: a practice by a regional core hospital in Japan to avoid physician burnout. <i>BMC Health Services Research</i> , 2023, 23, .	0.9	0
1079	Innate immune evasion strategies of SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	31
1080	Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Critical Care</i> , 2023, 27, .	2.5	12
1081	Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation. <i>Trends in Microbiology</i> , 2023, 31, 644-656.	3.5	7
1082	Inflammation as an exacerbation marker and target for prophylaxis against Coronavirus Disease 2019-related thrombosis. <i>International Journal of Medical Sciences</i> , 2023, 20, 136-141.	1.1	1
1083	Characteristics, outcomes, and risk factors for in-hospital mortality of COVID-19 patients: A retrospective study in Thailand. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1084	The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19. <i>Transplant Immunology</i> , 2023, 77, 101777.	0.6	0
1086	Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 1483-1494.	1.0	5
1088	Evaluation of the Treatment of Pregnant Women with COVID-19 Using the Drug Baricitinib. <i>Journal of Biochemical Technology</i> , 2022, 13, 71-75.	0.1	3
1089	Urine-based multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS. <i>Molecular Medicine</i> , 2023, 29, .	1.9	9
1090	Psoriatic arthritis and psoriasis in the era of COVID-19. , 2023, , 557-565.		0
1091	Dynamic activity in cis-regulatory elements of leukocytes identifies transcription factor activation and stratifies COVID-19 severity in ICU patients. <i>Cell Reports Medicine</i> , 2023, 4, 100935.	3.3	2
1092	Innate immune responses in COVID-19. , 2023, , 63-128.		0



#	ARTICLE	IF	CITATIONS
1093	The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19”Results from a pragmatic randomized clinical trial. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	2
1094	SARS-CoV-2 Pandemic-Therapeutics in Warp Speed. <i>Recent Advances in Anti-Infective Drug Discovery</i> , 2023, 18, 110-119.	0.4	2
1095	SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines. <i>Cancers</i> , 2023, 15, 632.	1.7	3
1096	Proteomic understanding of SARS-CoV-2 infection and COVID-19: Biological, diagnostic, and therapeutic perspectives. , 2023, , 61-85.		0
1097	Investigation on the Essential Oils of the Achillea Species: From Chemical Analysis to the In Silico Uptake against SARS-CoV-2 Main Protease. <i>Life</i> , 2023, 13, 378.	1.1	0
1098	In silico study of mechanism of neem leaf ( <i>Azadirachta indica</i> ) active compound inhibits SARS CoV2 infection through inhibition of ACE2 and CD209 receptors. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
1099	COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. <i>Critical Care</i> , 2023, 27, .	2.5	31
1100	A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. <i>PLoS ONE</i> , 2023, 18, e0274243.	1.1	0
1101	Remdesivir for the treatment of COVID-19. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	17
1102	JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte”endothelial proadhesive interactions. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1366-1380.	1.9	8
1103	Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19*. <i>Critical Care Medicine</i> , 2023, 51, 337-346.	0.4	11
1105	Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
1106	Corticosteroid outcome may be dependent of duration of use in severe COVID-19. <i>Korean Journal of Internal Medicine</i> , 2023, 38, 382-392.	0.7	4
1107	Effect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study. <i>Nutrients</i> , 2023, 15, 1736.	1.7	7
1108	SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo. <i>Microorganisms</i> , 2023, 11, 1015.	1.6	8
1109	Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. <i>Journal of the American Academy of Dermatology</i> , 2023, 89, 1248-1250.	0.6	0
1110	Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years. <i>Aging and Health Research</i> , 2023, 3, 100130.	0.5	2
1111	TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial. <i>Thorax</i> , 2023, 78, 816-824.	2.7	3

#	ARTICLE	IF	CITATIONS
1113	The development of COVID-19 treatment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	59
1114	Using risk factors and markers to predict bacterial respiratory co-/superinfections in COVID-19 patients: is the antibiotic stewardship's toolbox full or empty?. <i>Acta Clinica Belgica</i> , 2023, 78, 418-430.	0.5	1
1115	Identifying potential pharmacological targets and molecular pathways of Meliae cortex for COVID-19 therapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1116	An overview on the treatments and prevention against COVID-19. <i>Virology Journal</i> , 2023, 20, .	1.4	19
1117	The Role of Nutrition in Mitigating the Effects of COVID-19 from Infection through PASC. <i>Nutrients</i> , 2023, 15, 866.	1.7	5
1118	Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study. <i>Infection</i> , 2023, 51, 1033-1049.	2.3	8
1119	Impact of COVID-19 on Cardiovascular Disease. <i>Viruses</i> , 2023, 15, 508.	1.5	15
1120	Current and Emerging Therapies for COVID-19 in Lung Transplantation. <i>Current Pulmonology Reports</i> , 2023, 12, 23-35.	0.5	1
1121	Insights into COVID-19-associated critical illness: a narrative review. <i>Annals of Translational Medicine</i> , 2023, 11, 220-220.	0.7	2
1122	Severe COVID-19-associated hyperinflammatory syndrome versus classic hemophagocytic lymphohistiocytosis: similarities, differences, and the way forward. <i>Journal of Investigative Medicine</i> , 2023, 71, 244-253.	0.7	0
1123	In silico assessment on TdP risks of drug combinations under CiPA paradigm. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
1124	Transcranial direct current stimulation associated with pharmacological approaches in patients infected by SARS-CoV-2. <i>Revista Da Associação Médica Brasileira</i> , 2023, 69, 370-371.	0.3	0
1125	Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19*. <i>Critical Care Medicine</i> , 2023, 51, 413-415.	0.4	0
1126	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401.	1.8	4
1127	The role of interleukin-6 and janus kinases in the pathogenesis, and treatment of SARS-CoV-2. <i>Journal of Lung, Pulmonary &amp; Respiratory Research</i> , 2022, 9, 17-32.	0.3	1
1128	Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?. <i>Inflammopharmacology</i> , 2023, 31, 633-651.	1.9	9
1129	Hepatitis: infections and systemic causes. , 2023, , 487-524.		1
1130	Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF- $\beta$ 1 Signaling Pathway. <i>Molecules</i> , 2023, 28, 2195.	1.7	8

#	ARTICLE	IF	CITATIONS
1131	Repurposing Astragalus Polysaccharide PG2 for Inhibiting ACE2 and SARS-CoV-2 Spike Syncytial Formation and Anti-Inflammatory Effects. <i>Viruses</i> , 2023, 15, 641.	1.5	2
1132	Evaluation of the Effectiveness of Remdesivir in the Treatment of COVID-19 Outpatients: A retrospective cohort study. <i>Current Drug Therapy</i> , 2023, 18, .	0.2	0
1133	Single-Center Experience With the Seraph-100 <sup>®</sup> Microbind <sup>®</sup> Affinity Blood Filter in Patients With SARS-CoV-2 Infection and Septic Shock at a Military Treatment Facility. <i>Military Medicine</i> , 2023, 188, e2670-e2674.	0.4	3
1134	An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation. <i>Cells</i> , 2023, 12, 778.	1.8	6
1136	Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, 1727-1739.	0.9	1
1137	Identification, Synthesis, and Characterization of Novel Baricitinib Impurities. <i>ACS Omega</i> , 2023, 8, 9583-9591.	1.6	3
1138	Development of an External Control Arm Using Electronic Health Record-Based Real-World Data to Evaluate the Efficacy of COVID-19 Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 1274-1283.	2.3	2
1139	Targeted immunomodulation: a primer for intensivists. <i>Intensive Care Medicine</i> , 2023, 49, 462-464.	3.9	0
1140	Immunomodulators for severe coronavirus disease-2019 in transplant patients: Do they increase the risk of secondary infection?. <i>Transplant Infectious Disease</i> , 2023, 25, .	0.7	3
1141	Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing. <i>Heliyon</i> , 2023, 9, e14115.	1.4	1
1143	Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
1144	Treating COVID-19: Targeting the Host Response, Not the Virus. <i>Life</i> , 2023, 13, 712.	1.1	2
1145	Drug-Repurposing Screening Identifies a Gallic Acid Binding Site on SARS-CoV-2 Non-structural Protein 7. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 578-586.	2.5	3
1146	Elucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chips. , 2023, 2, .		5
1147	Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX "REVOLUTION" trial. <i>The Lancet Regional Health Americas</i> , 2023, 20, 100466.	1.5	1
1148	5. Clinical Practice of Respiratory Infectious Diseases in the "with/after COVID-19 Era". <i>The Journal of the Japanese Society of Internal Medicine</i> , 2022, 111, 578-584.	0.0	0
1149	Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
1150	Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2. <i>Molecular Immunology</i> , 2023, 156, 111-126.	1.0	5

#	ARTICLE	IF	CITATIONS
1151	Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry. <i>Therapeutic Advances in Hematology</i> , 2023, 14, 204062072311547.	1.1	3
1152	Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	9
1153	Anti-cytokine Therapy in Critical Illness: Is There a Role?. <i>Lessons From the ICU</i> , 2023, , 277-297.	0.1	0
1154	Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study. <i>Life</i> , 2023, 13, 755.	1.1	1
1155	Targeting intracellular pathways in idiopathic inflammatory myopathies: A narrative review. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
1156	A deep look into the storm: Israeli multi-center experience of coronavirus disease 2019 (COVID-19) in patients with autoimmune inflammatory rheumatic diseases before and after vaccinations. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1157	Hemophagocytic Syndrome and COVID-19: A Comprehensive Review. <i>Cureus</i> , 2023, , .	0.2	0
1158	Increased Inflammation and Treatment of Depression: From Resistance to Reuse, Repurposing, and Redesign. <i>Advances in Neurobiology</i> , 2023, , 387-416.	1.3	1
1159	Modulation of gut microbiota as a potential therapy to manipulate drug-induced hepatic damage in COVID-19 patients. <i>World Journal of Gastroenterology</i> , 0, 29, 1708-1720.	1.4	3
1160	COVID-19 and the Genetics of Inflammation. <i>Critical Care Medicine</i> , 2023, 51, 817-825.	0.4	3
1161	Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	10
1162	COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices. <i>Viruses</i> , 2023, 15, 787.	1.5	5
1163	Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 475-493.	1.9	1
1165	The COVID-19 Pandemic and Adult Cardiac Transplantation: Impact, Interventions, and Implications. <i>Canadian Journal of Cardiology</i> , 2023, 39, 853-864.	0.8	1
1166	Use of baricitinib in treatment of COVID-19: a systematic review. <i>Medicinal Research Reviews</i> , 0, , .	5.0	1
1167	Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
1168	Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance. <i>Journal of Inflammation</i> , 2023, 20, .	1.5	2
1169	Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline. <i>Drugs</i> , 2023, 83, 479-496.	4.9	2

#	ARTICLE	IF	CITATIONS
1170	Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. World Journal of Clinical Cases, 0, 11, 2140-2159.	0.3	1
1171	Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19. World Journal of Clinical Cases, 0, 11, 2168-2180.	0.3	2
1172	Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Clinical Infectious Diseases, 2023, 77, 186-193.	2.9	1
1173	Hyperinflammation and complement in COVID-19. American Journal of Hematology, 2023, 98, .	2.0	10
1174	Current thoughts on cellular functions of numb-associated kinases. Molecular Biology Reports, 2023, 50, 4645-4652.	1.0	2
1175	Host-Based Treatments for Severe COVID-19. Current Issues in Molecular Biology, 2023, 45, 3102-3121.	1.0	3
1176	Therapeutics for COVID-19. , 2024, , 282-307.		0
1177	Impact of Maternal SARS-CoV-2 Infection on the Fetus and Newborn. , 2024, , 235-252.		0
1178	Immunology of COVID-19. , 2024, , 52-71.		0
1180	Kidney Manifestations of COVID-19. , 2024, , 203-217.		0
1181	TREM2+ and interstitial-like macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques. Nature Communications, 2023, 14, .	5.8	10
1182	Clinical trial experience in Japan and future issues in developing drugs to treat COVID-19. Global Health & Medicine, 2023, , .	0.6	0
1183	Treatment options for patients with severe COVID-19. Global Health & Medicine, 2023, 5, 99-105.	0.6	1
1184	Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment. Immunological Medicine, 2023, 46, 121-130.	1.4	0
1185	Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19. JAMA - Journal of the American Medical Association, 2023, 329, 1170.	3.8	13
1186	Identification the genetic influence of SARS-CoV-2 infections on IgA nephropathy based on bioinformatics method.. Kidney and Blood Pressure Research, 0, , .	0.9	0
1187	A critical review on quercetin bioflavonoid and its derivatives: Scope, synthesis, and biological applications with future prospects. Arabian Journal of Chemistry, 2023, 16, 104881.	2.3	4
1188	Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies. World Journal of Gastroenterology, 0, 29, 2064-2077.	1.4	4

#	ARTICLE	IF	CITATIONS
1189	Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	4
1190	A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions. <i>Npj Systems Biology and Applications</i> , 2023, 9, .	1.4	3
1191	Role of baricitinib in COVID-19 patients: A systematic review and meta-analysis. <i>World Journal of Meta-analysis</i> , 0, 11, 125-133.	0.1	2
1192	Severe COVID-19: Drugs and Clinical Trials. <i>Journal of Clinical Medicine</i> , 2023, 12, 2893.	1.0	0
1193	Combination therapy with predicted body weight-based dexamethasone, remdesivir, and baricitinib in patients with COVID-19 pneumonia: A single-center retrospective cohort study during 5th wave in Japan. <i>Respiratory Investigation</i> , 2023, 61, 438-444.	0.9	0
1194	Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1195	The effect of medical innovation on the cost-effectiveness of Covid 19-related policies in the United States using a SIR model. <i>BMC Health Services Research</i> , 2023, 23, .	0.9	0
1196	Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	2
1197	Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475.	21.5	112
1198	COVID-19 and Multiorgan Response: The Long-Term Impact. <i>Current Problems in Cardiology</i> , 2023, 48, 101756.	1.1	2
1220	COVID-19 and Hematopoietic Stem Cell Transplantation. , 2023, , 177-192.		0
1243	Antiviral Drugs for SARS-CoV-2 and COVID-19. , 2023, , 211-223.		0
1248	Genetic Associations with Coronavirus Susceptibility and Disease Severity. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 119-140.	0.8	1
1335	Management of Immunosuppressed Dermatology Patients During COVID-19. <i>Updates in Clinical Dermatology</i> , 2023, , 109-120.	0.1	0
1345	Clinical course and management of COVID-19 in the era of widespread population immunity. <i>Nature Reviews Microbiology</i> , 2024, 22, 75-88.	13.6	1
1352	Cytokine storm in COVID-19 and other diseases: emerging therapeutic interventions. , 2024, , 209-241.		0
1366	Update in Pediatric Hospital Medicine. , 2023, , 449-477.		0